document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share exclude share registrant common stock hold executive officer director stockholder ownership exceed common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registranttable content gilead sciences inc annual report table content item business item risk factor item b unresolved staff comment item property item legal proceeding item submission matter vote security holder ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item principal accounting fee service iv item exhibit financial statement schedule signature right trademark copyright trade name business include follow gilead gilead science hepsera viread vistide daunoxome ambisome emtriva truvada macugen registered trademark belong osi pharmaceuticals inc sustiva videx register trademark baraclude trademark bristolmyers squibb company tamiflu register trademark belong f hoffmannla roche ltd retrovir trizivir combivir register trademark epzicom trademark glaxosmithkline inc cancidas register trademark belong merck co inc report include trademark service mark trade name companiestable content annual report include management discussion analysis financial condition result operation contain forward look statement future event future result subject safe harbor create securities act securities act securities exchange act exchange act word expect anticipate target goal project intend plan believe seek estimate continue variation word similar expression intend identify forwardlooke statement addition statement refer projection future financial performance anticipate growth trend business characterization future event circumstance forwardlooke statement base forward look statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forward look statement reason include identify risk factor beginning give risk uncertainty caution place undue reliance forward look statement forward look statement include report date hereof require federal security law rule regulation securities exchange commission sec undertake specifically decline obligation update statement publicly announce result revision forward look statement distribution report result new information future event change assumption item business overview gilead sciences inc biopharmaceutical company discover develop commercialize therapeutic advance care patient suffer lifethreatening disease multinational company revenue approve product marketing operation country focus research clinical program antiinfective seek add exist portfolio product internal discovery clinical development program active product acquisition inlicense strategy annual report gilead word similar import reference gilead sciences inc consolidate subsidiary worldwide headquarters foster city california incorporate delaware june mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website financial information available follow filing soon reasonably practicable electronically file furnished sec annual report quarterly report form q current report form k amendment report file furnish pursuant section security exchange act filing available free charge product viread tenofovir disoproxil fumarate oral formulation nucleotide analogue reverse transcriptase inhibitor dose day combination therapy treat human immunodeficiency virus hiv infection adult promote viread united states commercial team sell united states exclusively wholesale channel promote sell viread major european country european commercial team distributor certain latin american country distributor promote sell viread japan corporate partner japan tobacco inc japan tobacco exclusive worldwide license patent right relate technology viread institute organic chemistry biochemistry academy sciences czech republic rega stichting vzw iocbrega table content truvada emtricitabine tenofovir disoproxil fumarate oral formulation dose day combination therapy treat hiv infection adult fixeddose combination antihiv medication viread emtriva promote truvada united states commercial team sell united states exclusively wholesale channel follow regulatory approval february commence promotion sale truvada european union european commercial team distributor promote sell truvada japan corporate partner japan tobacco exclusive worldwide license patent right relate technology viread emtriva component truvada iocbrega emory university emory respectively emtriva emtricitabine oral formulation nucleoside analogue reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult united states europe emtriva approve combination therapy treat hiv infection child promote emtriva united states commercial team sell united states exclusively wholesale channel promote sell emtriva major european country european commercial team distributor certain latin american country distributor promote sell emtriva japan corporate partner japan tobacco exclusive worldwide license patent right relate technology emtriva emory ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat invasive fungal infection cause fungal specie corporate partner astellas pharma inc astellas successor fujisawa usa inc promote sell ambisome united states promote sell ambisome major country europe european commercial team hepsera adefovir dipivoxil oral formulation nucleotide analogue hepatitis b virus hbv dna polymerase inhibitor dose day treat chronic hepatitis b hepsera approve sale united states treatment chronic hepatitis b adult evidence active viral replication evidence persistent elevation serum aminotransferase alt ast histologically active liver disease commercial team promote hepsera united states sell united states exclusively wholesale channel promote sell hepsera major european union country european commercial team distributor license right commercialize hepsera solely treatment hepatitis b asia latin america certain territories glaxosmithkline inc gsk begin sell hepsera japan republic korea taiwan china exclusive worldwide license patent right relate technology hepsera iocbrega vistide cidofovir injection antiviral medication treatment cytomegalovirus cmv retinitis patient acquire immunodeficiency syndrome aid vistide approve sale united states promote vistide united states commercial team sell united states exclusively wholesale channel country outside united states vistide sell pfizer inc pfizer successor pharmacia corporation daunoxome liposomal daunorubicin injection liposomal formulation anticancer agent daunorubicin approve sale united states europe certain country treatment aidsrelate kaposis sarcoma gilead sell product limited number country currently evaluate supply sale strategy regard product table content follow table list aggregate product sale major product thousand product product product sale sale sale hiv product viread truvada emtriva total hiv product ambisome hepsera vistide daunoxome total product sale item note consolidated financial statement page include annual report product sale geographic area royalty product tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu class prescription drug call neuraminidase inhibitor tamiflu approve treatment influenza child adult country include united states japan countries european union approve prevention influenza child adults united states japan countries european union develop tamiflu f hoffmannla roche ltd roche roche exclusive right manufacture party sell tamiflu worldwide subject obligation pay percentage net revenue roche generate tamiflu sale macugen pegaptanib sodium injection antiangiogenic injection treatment neovascular agerelate macular degeneration macugen approve food drug administration fda united states december sale commence january february product receive marketing approval sale european union macugen develop eyetech pharmaceuticals inc eyetech technology license promote united states osi pharmaceuticals inc osi successor eyetech pfizer osi hold exclusive right manufacture sell macugen worldwide subject osis obligation pay percentage net revenue osi generate macugen sale commercialization distribution international commercial sale operation marketing subsidiary australia canada france germany greece ireland italy new zealand portugal spain united kingdom united states commercial team promote hiv hbv product viread truvada emtriva hepsera direct field contact physician hospital clinic healthcare provider involve treatment patient hiv hiv product chronic hepatitis b hepsera sell hiv product hepsera united states exclusively wholesale channel corporate partner astella promote sell ambisome united states sell hiv product hepsera ambisome major european country european commercial team distributor table content promote sell distribute product country outside united states europe include country asia latin america middle east africa certain territory enter agreement party distributor grant exclusive right sell product particular territory specify period time agreement provide collaborative effort distributor obtain regulatory approval product specify territory agreement generally grant distributor right market product territory generally establish price distributor pay product require deliver quantity product order distributor competition product development program target number disease condition include viral fungal infection commercially available product disease large number company institution spend considerable amount money resource develop additional product treat disease current product compete available product base primarily efficacy safety tolerability acceptance doctor patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing adaptability mode dose hiv product hiv landscape competitive complex treatment trend continue evolve grow number antihiv drug currently sell advanced stage clinical development approximately brand drug available united states hiv product primarily compete fixeddose combination product nucleotidenucleoside reverse transcriptase inhibitor nrti class include combivir azt tc epzicom tc abc trizivir azttcabc sell gsk company hiv product compete nrti class include bristolmyers squibb company bms roche hiv product compete broadly hiv product boehringer ingelheim merck co inc merck abbott laboratories bmss videx ec didanosine generic hiv product united states gsk retrovir azt face generic competition united states result launch generic azt little impact generic didanosine generic azt price gilead hiv product price decrease hiv product result ambisome ambisome face strong competition current expect competitor competition current expect competitor erode revenue receive sale ambisome ambisome primarily compete vfend voriconazole develop pfizer caspofungin product develop merck market cancidas united states caspofungin ambisome compete lipidbase amphotericin b product include abelcet amphotericin b lipid complex injection sell enzon pharmaceuticals inc united states canada japan table content medeus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sell river pharmaceutical llc worldwide bms numerous generic manufacturer sell conventional amphotericin b compete ambisome presently unapproved expect competitor class treatment call echinocandin include astella micafungin receive marketing approval japan october review regulatory approval united states canada anidulafungin pfizer vicuron inc product candidate evaluate multiple latestage clinical trial finally schere plough develop noxafil posaconazole currently phase trial recently receive positive opinion european regulator aware report lipid formulation claim similarity ambisome available outside united states include anticipate entry formulation greece impact formulation sale ambisome unknown formulation compete market ambisome hepsera hepsera face significant competition exist expect therapy treat patient infect hbv hepsera compete primarily antiviral product baraclude entecavir oral nucleoside analogue develop bms launch united states epivir hbv lamivudine develop gsk collaboration shire pharmaceutical shire sell major country north south america europe asia hepsera face competition clinicalstage candidate include telbivudine oral nucleoside analogue develop novartis pharmaceutical corporation novartis idenix pharmaceutical limited idenix currently review approval united states europe pradefovir mesylate oral antiviral compound develop valeant pharmaceutical international currently phase trial hepsera competes establish immunomodulatory therapy include introna interferon alfab sell schere plough major country north south america europe asia pegasys pegylate interferon alfaa injectable drug similar introna sell roche treatment hbv vistide vistide compete number drug treat cmv retinitis include cytovene iv cytovene ganciclovir sell intravenous oral formulation roche ocular implant bausch lomb incorporate valcyte valganciclovir market roche foscavir foscarnet intravenous drug sell astrazeneca vitravene fomivirsen drug inject directly eye sell cibavision tamiflu tamiflu compete relenza zanamivir antiinfluenza drug sell gsk relenza neuraminidase inhibitor deliver orallyinhale dry powder generic competitor include amantadine rimantadine oral tablet inhibit replication influenza virus biocryst pharmaceuticals inc develop injectable formulation peramivir influenza neuraminidase inhibitor treatment influenza currently preclinical trial macugen macugen compete primarily visudyne verteporfin injection sell novartis pharmaceutical corporation connection photodynamic therapy genentech inc develop lucentis ranibizumab currently phase trial pende fda approval approve compete directly macugen number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently biopharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program table content anticipate face increase competition future competitor introduce new product market new technology available determine exist product new product competitor develop effective effectively market sell develop competitive product render technology product obsolete noncompetitive recover money resource develop product collaborative relationship business strategy establish collaboration company university medical research institution assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire product right product technology complementary business company university medical research institution information relationship include financial accounting impact business find item note consolidated financial statement page include annual report commercial collaboration follow list representative commercial collaboration year collaboration partner program area sign roche tamiflu emory emtricitabine iocbrega viread truvada hepsera vistide japan tobacco viread truvada emtriva gsk hepsera pfizer macugen vistide osi liposome product macugen sumitomo ambisome md anderson cancer center hepsera astella ambisome ulehi selex f hoffmannla roche ltd hoffmannla roche inc roche september enter development license agreement roche develop commercialize therapy treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codevelope roche original agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay percentage net sale roche generate tamiflu sale june deliver notice termination roche material breach original agreement november resolve dispute roche agree terminate relate arbitration proceed pende party connection dispute resolution enter amendment supplement original agreement roche amendment eliminate cost good adjustment royalty calculation retroactive calendar year future calculation amendment provide formation joint manufacturing committee review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu commercial committee evaluate commercial plan strategy tamiflu united states joint supervisory committee evaluate roche overall commercial plan tamiflu global basis committee consist representative gilead roche amendment option provide specialized sale force supplement roche marketing effort tamiflu table content emory university emory april triangle pharmaceuticals inc triangle obtain january acquire acquisition triangle exclusive worldwide license emorys right purify form emtricitabine use hiv hbv indication prior july pay royalty emory respect worldwide net sale product contain emtricitabine july royalty pharma purchase respectively royalty interest own emory exchange elimination emtricitabine royalty payable emory july pay royalty respect worldwide net sale product contain emtricitabine directly royalty pharma rate proportional share purchase price july payment emory connection amendment restatement exist license agreement emory pertain obligation develop emtricitabine hepatitis b indication institute organic chemistry biochemistry academy sciences czech republic rega stichte iocbrega enter agreement iocbrega relate certain nucleotide compound discover institution agreement receive exclusive right manufacture use sell nucleotide compound obligate pay iocbrega percentage net revenue receive sale product contain compound subject minimum royalty payment product cover original agreement include vistide hepsera viread december agreement iocbrega amend provide reduce royalty rate future sale product incorporate adefovir active ingredient hepsera tenofovir active ingredient viread truvada return upfront payment sign amendment august agreement iocbrega amend include truvada future fixeddose combination product contain license technology iocbrega agree waive right royalty sale viread truvada develop country sell product cost gilead access program japan tobacco inc japan tobacco july enter licensing agreement japan tobacco japan tobacco commercialize hiv product portfolio specifically viread truvada emtriva japan term agreement receive upfront license fee entitle receive additional cash payment achievement certain milestone japan tobacco require pay royalty net sale product japan march viread approve sale japan march emtriva truvada approve sale japan glaxosmithkline inc gsk april enter licensing agreement gsk provide gsk right commercialize hepsera asia latin america certain territory agreement retain right hepsera united states canada eastern western europe australia new zealand turkey gsk receive exclusive right develop hepsera solely treatment chronic hepatitis b territory significant include china japan republic korea taiwan receive upfront license fee certain milestone payment entitle receive additional payment achievement certain milestone gsk responsibility development commercialization hepsera territory addition gsk require pay royalty net product sale hepsera gsk hepatitis product epivirhbvzeffix gsk territory hepsera launch japan republic korea taiwan china pfizer inc pfizer december osi successor eyetech grant pfizer sublicense relate macugen connection sublicense enter license pfizer term contain agreement osi december enter agreement osi fill finish macugen osi year macugen approve fda united states december sale commence january february product receive marketing approval sale european union table content enter agreement pfizer successor pharmacia corporation relate vistide agreement pfizer exclusive right market sell vistide country outside united states subject payment percentage net product sale require sell pfizer bulk cidofovir maintain vistide patent connection agreement receive upfront license fee cash payment obtain marketing approval europe certain royalty net sale vistide osi pharmaceuticals inc osi december complete sale oncology asset osi term agreement entitle additional payment osi cash combination cash osi stock osi reach certain development milestone nx advanced oncology product candidate sell osi relate manufacturing agreement produce nx gs l liposomal drug candidate include sale march enter agreement osi successor eyetech relate macugen term agreement osi worldwide right therapeutic use macugen responsible research development cost entitle cash payment osi osi reach certain milestone royaltie worldwide net sale macugen december enter agreement osi fill finish macugen osi year dainippon sumitomo pharma co ltd sumitomo september enter agreement sumitomo pursuant sumitomo agree develop market ambisome japan term agreement receive upfront license fee addition entitle receive additional payment certain clinical commercial milestone meet receive royalty ambisome sale japan md anderson cancer center enter agreement md anderson cancer center relate hepsera connection agreement pay upfront license fee require pay md anderson cancer center percentage net sale base sale hepsera astellas pharma inc astellas enter agreement astella successor fujisawa usa inc relate right market ambisome agreement amend astella responsible promotion ambisome united states astellas sole marketing right ambisome canada exclusive marketing right ambisome rest world provide pay royalty astellas connection sale significant market asia include china india japan korea taiwan astellas collect payment sale ambisome united states canada entitle receive royalty base specified percentage astella gross profit sale ambisome united states canada university license equity holdings inc ulehi ongoing collaborative arrangement ulehi successor university technology corporation predecessor university research corporation technology hold company university colorado boulder relate identification aptamer oligonucleotide diagnostic therapeutic application selex technology arrangement ulehi grant present future right invention cover patent patent application selex technology improvement selex technology make discover oligonucleotide molecule make selex technology computer software relate selex technology require pay ulehi royalty base revenue generate sale product derive selex technology include revenue base license agreement osi relate macugen ulehi assign royalty income capital royalty partner lp pursuant consent agreement sign connection assignment pay royalty obligation relate selex process patent capital royalty partner lp table content develop world collaboration follow list representative develop world collaboration aspen pharmacare october enter nonexclusive manufacture distribution agreement aspen pharmacare provide manufacture distribution viread truvada certain develop world country include gilead access program gilead access program december establish gilead access program pursuant agree sell viread cost develop country africa caribbean latin america southeast asia expand access program august include truvada august announce significant price reduction viread truvada available gilead access program step ensure viread truvada sell program serve patient develop world divert market institute world health january enter agreement institute world health pursuant provide ambisome cost phase clinical trial evaluate ambisome treatment visceral leishmaniasis paromomycin india great global burden visceral leishmaniasis clinical trial conduct institute world health partnership world health organization dart study november enter collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conduct mrc antiretroviral hiv therapy africa trial call dart study development antiretroviral therapy aim study clinical versus laboratory monitoring practice structure treatment interruption continuous antiretroviral therapy adult hiv infection subsaharan africa provide viread cost dart study bill melinda gates foundation family health international october enter agreement bill melinda gates foundation family health international fhi provide viread fhis multinational clinical trial evaluate viread effectiveness method reduce risk hiv infection sexually active adult regularly expose hiv clinical trial conduct fhi funded million grant gate foundation research collaboration follow list representative research collaboration collaboration partner program area year sign japan tobacco gs know jtk treatment hiv bm truvadasustiva fixeddose regimen treatment hiv achillion gs know ach treatment hepatitis c hcv genelabs nucleoside rna polymerase inhibitor treatment hcv chiron small molecule therapeutic certain hcv drug target japan tobacco march enter licensing agreement japan tobacco japan tobacco grant gilead exclusive right develop commercialize novel hiv integrase inhibitor gs know jtk country world exclude japan table content japan tobacco retain right term agreement pay upfront license fee additionally obligate additional cash payment achievement certain milestone pay royalty base future net product sale territory market drug bristolmyers squibb company bms december enter collaboration bms develop commercialize fixeddose regimen truvada bmss sustiva efavirenz united states bms structure collaboration joint venture form limited liability company call bristolmyers squibb gilead sciences llc term collaboration bms grant royaltyfree license joint venture use respective companyowne technology return grant license joint venture use intellectual property result collaboration ownership interest joint venture bm reflect respective economic interest base fraction estimate net selling price fixeddose regimen product attributable truvada sustiva respectively adjust annual basis net selling price truvada change time relative net selling price sustiva bmss respective economic interest joint venture vary annually primary responsibility clinical development activity regulatory filing relate new product result collaboration bms share marketing sale effort party provide equivalent sale force effort minimum number year daily operation joint venture govern primary joint committee responsible accounting financial reporting product distribution joint venture january gilead bms announce obtain datum support bioequivalence new formulation fixeddose combination product gilead bms anticipate file new drug application nda fda second quarter achillion pharmaceuticals inc achillion november enter exclusive license collaboration agreement achillion pursuant agreement grant worldwide right research development commercialization certain small molecule hcv replication inhibitor involve hcv protease treatment hepatitis c collaboration achillion obligate continue development compound accord mutually agree development plan completion proofofconcept clinical study hcvinfecte patient cost incur achieve proofofconcept share equally gilead achillion contractually agree budget follow proofofconcept study obligate assume responsibility incur cost associate development commercialization compound warrant development achillion option participate commercialization effort future product arise collaboration conjunction signing collaboration pay upfront license fee equity investment achillion convertible prefer stock agree payment achillion achievement certain milestone outline agreement pay royalty future net sale product arise collaboration achillion begin dose healthy volunteer phase clinical study gs know ach treatment hepatitis c genelabs technologies inc genelabs september enter license research collaboration agreement genelab research develop commercialize certain genelab novel nucleoside inhibitor hcv polymerase treatment chronic infection cause hcv conjunction signing agreement pay upfront license fee initial term year term extend additional year gilead option genelab obligate lead research effort agree provide annual funding fulltime equivalent lead development commercialization activity obligate additional payment achievement certain milestone pay royalty future net sale select compound develop approve relation collaboration table content chiron corporation chiron august enter nonexclusive licensing agreement chiron research development commercialization small molecule therapeutic select hcv drug target agreement receive nonexclusive right use chiron hcv technology develop commercialize product treatment hcv term agreement pay chiron upfront license fee agree additional payment certain clinical regulatory contractually determined milestone meet additionally obligate royalty payment event product develop licensed technology research development addition enter collaboration company university medical research institution seek add exist portfolio product internal discovery clinical development program active inlicense product acquisition strategy acquisition triangle complete january research scientist foster city san dimas california durham north carolina engage discovery development new molecule technology hope lead new medicine novel formulation exist drug therapeutic focus area life threaten infectious disease internal research focus discovery development treatment viral infection particularly hiv hbv hcv hiv file investigational new drug ind application december gs internal integrase clinical candidate initiate phase clinical study healthy volunteer february january announce complete phase study gs novel hiv integrase inhibitor license japan tobacco base result study gilead anticipate initiate phase clinical trial second quarter hepatitis b progress enrollment phase study compare efficacy safety tenofovir df active pharmaceutical ingredient viread versus hepsera patient hepatitis b anticipate complete enrollment second half addition technology license chiron inhouse program design discover small molecule inhibitor hcv rna polymerase hcv protease believe small molecule therapeutic treatment hepatitis c day lead well treatment outcome patient program require extensive investment year total research development expense million compare million million patent proprietary right patent proprietary right important business properly design enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology rely trade secret internal knowhow technological innovation agreement party develop maintain protect competitive position ability competitive depend success strategy number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent table content follow table show actual estimate expiration date united states europe primary patent patent issue pende application cover compound market product european patent patent product expiration expiration daunoxome vistide hepsera ambisome tamiflu macugen viread emtriva truvada patent cover viread hepsera vistide emtriva truvada hold party acquire exclusive right patent agreement party commercial collaboration patent cover active ingredient ambisome instead hold patent liposomal formulation compound protect formulation trade secret patent filing cover form adefovir dipivoxil active ingredient hepsera china certain country asia application pende country asia include china relate specific form formulation hepsera asia major market therapie hbv indication hepsera develop obtain patent certain product year obtain marketing approval product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension example extension patent vistide grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain important infringe patent proprietary right violate agreement grant proprietary right infringe patent violate agreement prevent develop selling product process cover patent agreement require obtain license party allow use technology certain require obtain license thirdparty technology obtain reasonable cost able obtain require license adversely affect patent application confidential period time patent issue know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete patent competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive ultimately successful patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation reexamination proceeding enforcement validity exist patent future patent invalidate patent substantially reduce protection addition pende patent application patent table content application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product develop develop addition certain country africa asia include china permit enforcement patent manufacturer able sell generic version product country approval process product fda determine product grant exclusivity period manufacturer application approval generic version product grant generic manufacturer wait challenge patent protect product grant exclusivity year prior end exclusivity period time time receive notice manufacturer indicate intend import chemical intermediate possibly use make product possible generic manufacturer consider attempt seek fda approval similar identical drug abbreviate new drug application application form typically manufacturer seek approval generic drug patent subject challenge need spend significant resource defend challenge able defend patent successfully rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor research development agreement invention discover certain case jointly own corporate partner case exclusive property difficult determine own particular invention dispute arise invention manufacture raw material antiviral product commercialscale manufacturing facility antiviral product contract party manufacture antiviral drug clinical commercial purpose include viread truvada emtriva hepsera vistide tamiflu use party contract manufacturer manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread emtricitabine active pharmaceutical ingredient emtriva adefovir dipivoxil active pharmaceutical ingredient hepsera cidofovir active pharmaceutical ingredient vistide party contract manufacturer manufacture active pharmaceutical ingredient viread truvada hepsera tableting perform party contract manufacturer manufacture site qualify approve supply product united states european union market emtriva capsulation complete party contract manufacturer manufacturer approve supply product united states european union market second manufacturer qualify expect submission regulatory approval use single party manufacturer supply vistide drug product table content process instal additional filling packaging capability facility san dimas california dublin ireland regulatory approval allow fill package drug product viread truvada emtriva hepsera finish form roche party responsible manufacturing tamiflu agreement roche joint manufacturing committee compose representative gilead roche opportunity review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu future antiviral product need develop additional manufacturing capability establish additional party supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale unable develop manufacturing capability internally contract large scale manufacturing party acceptable term future antiviral product ability conduct large scale clinical trial meet customer demand commercial product adversely affect believe technology use manufacture product compound proprietary antiviral product disclose necessary aspect technology contract manufacturer enable manufacture product compound agreement manufacturer intend restrict reveal technology certain manufacturer comply restriction addition manufacturer develop technology relate work perform need manufacture product compound require enter agreement manufacturer want use technology allow manufacturer use technology manufacturer refuse allow use technology demand term use technology acceptable ambisome manufacture ambisome commercial quantity facilities san dimas medicines control agency united kingdom fda approve commercial production ambisome facility produce import ambisome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging distribution european union use commercially available material equipment manufacture product currently obtain amphotericin b active pharmaceutical ingredient ambisome cholesterol use manufacture ambisome single approve supplier ambisome sell freezedrie product currently freezedry fill ambisome san dimas manufacturing facility use party freezedry fill additional product need give current projection ambisome demand believe sufficient capacity meet future demand option instal additional freezedrying capacity san dimas additional supply necessary macugen manufacture macugen commercial quantity fda approve facilities san dimas manufacturing agreement osi use commercially available material equipment produce fill product currently osi provide syrinx raw material manufacture macugen include pegaptanib sodium active pharmaceutical ingredient macugen single approve supplier contract osi give osis current projection macugen demand believe sufficient capacity meet future demand process instal additional production filling capacity san dimas table content unsuccessful installation additional production filling capacity san dimas locate appropriate party meet need ability meet increase macugen demand diminish material utilize operation facility supplier key component material name nda file fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship viread ambisome hepsera emtriva truvada vistide supply product development clinical trial seasonal operation backlog worldwide product sale reflect significant degree seasonality contract royalty revenue represent total revenue affect seasonality example royalty revenue receive roche sale tamiflu impact severity associate flu season planning response avian influenza pandemic threat operate market characterize short lead time absence significant backlog believe backlog information material business government regulation operation activity subject extensive regulation numerous government authority united states countries united states drug subject rigorous fda regulation federal food drug cosmetic act federal state statute regulation govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume fda approve drug sell united states general process approval follow preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug potential safety benefit submit datum fda ind application seek approval test compound human clinical trial fda accept ind application study drug human clinical trial determine drug safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug give small number healthy human subject patient test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug give limited patient population determine effect drug treating disease well dose drug possible effect safety risk drug phase compound appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial longterm involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug uncommon drug appear promise phase clinical trial fail rigorous reliable phase clinical trial table content fda approval process believe datum phase clinical trial adequate level safety effectiveness file nda fda seek approval sell drug particular use fda review nda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug committee make recommendation fda binding generally follow fda fda agree compound meet require level safety effectiveness particular use allow sell drug united states use unusual fda reject application believe drug safe effective believe datum submit reliable conclusive point process development drug stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive postmarketing test surveillance monitor safety benefit product candidate determine nda contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california include san dimas facility foster city facility license state california compliance local regulatory requirement drug treat lifethreatening disease condition adequately address exist drug development program design address unmet medical need designate fast track product fda eligible accelerate priority review drug treatment hiv designate use president emergency plan aid relief pepfar qualify expedite priority review viread truvada receive accelerate approval priority review drug receive accelerated approval monitor postmarkete clinical trial order confirm safety benefit drug subject federal state local regulation workplace safety protection environment use hazardous material chemical viruse radioactive compound research development activity eliminate risk accidental contamination injury material misuse accident involve material lead significant litigation fine penalty drug subject extensive regulation outside united states european union centralize approval procedure authorize marketing product country european union include major country europe procedure approval country table content european union obtain approval country european union simplify application process mutual recognition procedure decentralize procedure rely principle mutual recognition receive regulatory approval european registration procedure pricing reimbursement approval require country price reimbursement successful commercialization depend availability governmental thirdparty payor reimbursement cost product government authority thirdparty payor increasingly challenge price medical product service particularly innovative new product therapie business adversely affect increase global pricing pressure united states number legislative regulatory change healthcare system impact pricing product december president bush sign law new medicare prescription drug coverage legislation legislation authorize center medicare medicaid services cms agency department health human service administer medicare implement new medicare coverage benefit prescription drug prescription drug program begin january factor influence possible impact gilead drug class cover payment level new medicare program lower previous medicare payment medicare patient pay coinsurance influence product recommend physicians select patient program enrollment mandatory dually eligible medicaid medicare assurance drug recognize new medicare program outpatient prescription drug pay level reflect current historical level federal medicare proposal state medicaid drug payment change healthcare reform lower payment product result operation materially adversely affect reimbursement change emerge medicare prescription drug coverage legislation extent private insurer blue cross blue shield manage care program follow medicaid coverage payment development adverse effect low medicare payment magnify private insurer adopt low payment additionally state enact health care reform legislation federal state development possible impact propose legislation reform unclear result pricing reimbursement restriction adversely impact revenue europe success viread truvada emtriva hepsera tamiflu depend largely obtain maintain government reimbursement european country patient use prescription drug reimburse government reimbursement available reimbursement policy adversely affect ability sell product profitable basis example europe international market government control price prescription pharmaceutical expect price prescription pharmaceutical decline life product volume increase new drug come market face significant price decrease product europe believe continue foreseeable future government struggle escalate health care spending result pricing practice difficult maintain historic level profitability achieve expect rate growth testing manufacturing marketing use product product development involve substantial risk product liability claim maintain product liability insurance successful product liability claim cover insurance require pay amount provide insurance impair financial condition ability clinically test market product table content health care fraud abuse law subject federal state law pertain health care fraud abuse include antikickback law false claim law antikickback law illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business include purchase prescription particular drug breadth statutory provision increase attention give law enforcement authority possible certain practice challenge antikickback similar law false claim law prohibit knowingly willingly present cause present payment thirdparty payor include medicare medicaid claim reimburse drug service false fraudulent claim item service provide claim claim medically unnecessary item service sale marketing activity subject scrutiny law violation fraud abuse law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid government allege convict violate law material adverse effect result operation compulsory license government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread currently engage discussion brazilian government affordability hiv product addition concern cost availability tamiflu fear grow potential avian flu pandemic generate international discussion potential compulsory licensing tamiflu patent addition roche issue voluntary license permit party manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override gilead tamiflu patent roche issue additional voluntary license permit thirdparty manufacturing tamiflu development reduce royalty receive roche sale tamiflu compulsory license generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale employee january approximately fulltime employee believe good relation employee environment seek comply applicable statutory administrative requirement concern environmental quality continue expenditure environmental compliance protection expenditure compliance environmental law expect material effect capital expenditure result operation competitive position table content item risk factor evaluate business carefully consider follow risk addition information annual report follow risk materially adversely affect business result operation financial condition note factor investor permit private security litigation reform act possible predict identify factor consider risk complete statement potential risk uncertainty face substantially revenue derive sale limited number product unable maintain continue increase sale hiv product result operation adversely affect currently dependent sale hiv product especially viread truvada support exist operation hiv product exclusively nucleoside class antiviral therapeutic treatment paradigm hiv change cause nucleosidebased therapeutic fall favor unable continue increase hiv product sale result operation likely suffer likely need scale operation include spend research development effort hiv product sale year end december billion total revenue sale viread truvada comprise respectively total hiv product sale able continue growth rate sale hiv product reason state risk factor section particular follow reason hiv product long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning label narrow approve indication halt sale product reduce revenue product mature private insurer government reimburser reduce reimburse patient product increase pressure reduce price large market hiv product consist patient take hiv drug successful encourage physician change patient regimen include hiv product sale hiv product limit generic hiv product introduce major market ability maintain pricing affect fail commercialize new product expand indication exist product prospect future revenue stock price adversely affect introduce new product increase revenue exist product able increase total revenue fail increase sale hiv product able increase revenue expand research development effort face difficulty collaboration effort bms commercialize onceaday single pill combination truvada sustiva example regulatory approval nda expect file fda second quarter grant timely basis face significant competition face significant competition business substantially great resource addition competitor product operate field compete long hiv product compete primarily product gsk market fixeddose combination product compete truvada ambisome encounter significant competition new product produce merck pfizer addition aware report lipid table content formulation claim similarity ambisome available outside united states include anticipate entry formulation greece hepsera encounter increase competition launch bmss baraclude entecavir potential future competition telbivudine develop novartis idenix await approval united states europe company significantly impede ability successful antiviral product ambisome significant safety issue arise market product sale decline adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case limit postapproval use safety efficacy study viread emtriva dose separate product ongoing underway long period time safety efficacy study truvada viread emtriva underway follow approval product long period time patient take numerous medicine underlie health problem monitor dose compliance drug long period time patient find expect continue find new issue safety resistance drug interaction issue require provide additional warning label narrow approve indication reduce market acceptance product safety resistance interaction issue arise market product sale product limit halt regulatory authority operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis achieve continued compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda comparable regulatory agency country continue clinical trial viread truvada emtriva ambisome hepsera currently approve additional use anticipate file marketing approval additional country additional product year product fail receive marketing approval timely basis addition market product manufacture sell product subject extensive continue regulation review discovery previously unknown problem market product problem manufacture promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution depend contract research organization result clinical trial uncertain support continue development product pipeline adversely affect prospect future revenue growth gilead extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely party contract research organization cro perform clinical study include document preparation site identification screen preparation pre study visit train program management dispute disruption relationship cro clinical trial delay addition require demonstrate safety effectiveness product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product table content product development fail achieve primary endpoint clinical trial safety issue arise commercialization drug candidate delay halt addition clinical trial involve commercial product raise new safety issue exist product turn reduce revenue manufacturing problem delay product shipment regulatory approval adversely affect result operation depend party perform manufacturing activity effectively timely basis party fail perform require impair ability deliver product timely basis cause delay clinical trial application regulatory approval event harm competitive position manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation manufacturer subject fda current good manufacturing practice extensive regulation govern manufacturing process stability testing recordkeeping quality standard similar regulation effect country addition manufacturing operation subject routine inspection regulatory agency depend party manufacturer manufacture viread truvada emtriva hepsera vistide include truvada viread available physician treatment program cost develop country access program rely party manufacture active pharmaceutical ingredient final drug product clinical commercial purpose addition roche party responsible manufacturing tamiflu thirdparty manufacturer develop problem control problem adversely affect business manufacture ambisome macugen facilities san dimas california formulation manufacturing facilities united states manufacturing facility ireland conduct quality control testing labeling packaging addition use party alternate contract supplier fill freeze dry certain batch product event natural disaster include earthquake equipment failure strike difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome macugen meet market need able obtain material necessary manufacture product limit ability generate revenue material utilize operation facility example depend single supplier high quality amphotericin b distearoylphosphatidylcholine high quality cholesterol manufacture ambisome supplier key component material name nda file fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship viread ambisome hepsera emtriva truvada vistide supply product development clinical trial depend relationship company sale marketing performance revenue failure maintain relationship poor performance company dispute company negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance include collaboration astella sumitomo ambisome gsk hepsera roche tamiflu pfizer vistide osi pfizer macugen japan tobacco viread truvada emtriva joint venture bms develop commercialize fixeddose regimen truvada sustiva country rely international distributor sale viread table content truvada emtriva ambisome hepsera outside united states relationship involve clinical development product partner reliance collaborative relationship pose number risk include able control corporate partner devote sufficient resource program product dispute arise future respect ownership right technology develop corporate partner disagreement corporate partner lead delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose devote few resource marketing product product development distributor corporate partner unable pay give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue exist product decline april licensing agreement gsk give gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major market hepsera china japan taiwan republic korea success hepsera territory depend entirely effort gsk regard gsk promote epivirhbvzeffix product compete hepsera consequently gsk marketing strategy hepsera influence promotion epivirhbv receive royalty gsk equal percentage gsk net sale hepsera net sale gsk epivirhbvzeffix gsk fail devote sufficient resource succeed develop commercialize hepsera territory potential revenue sale hepsera substantially reduce expense associate clinical trial sale fluctuation result inventory level hold wholesaler cause earning fluctuate adversely affect stock price clinical trial require regulatory approval product clinical trial require conduct approval extremely expensive difficult accurately predict control timing expense quarter quarter uneven unexpected spending program cause operating result fluctuate quarter quarter addition year end december approximately product sale united states wholesaler amerisourcebergen corp cardinal health inc mckesson corp inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match end user demand wholesaler enter inventory management agreement completely effective match inventory level end user demand estimate determine end user demand approximately half product sale occur outside united states currency fluctuation cause earning fluctuate adversely affect stock price significant percentage product sale denominate foreign currency primarily euro increase value dollar foreign currency past reduce future table content reduce dollar equivalent sale negatively impact financial condition result operation use foreign currency forward contract hedge percentage forecast international sale primarily denominate euro currency hedge portion account receivable balance denominate foreign currency reduce eliminate exposure currency fluctuation date sale record date cash collect hedge program hedge portion total exposure significant foreign exchange rate fluctuation short period time adversely affect result operation face credit risk european customer adversely affect result operation european product sale government own support customer greece italy portugal spain subject significant payment delay government funding reimbursement practice account receivable government own support customer country total million december historically receivables tend accumulate period time settle large lump sum payment government funding available significant change occur reimbursement practice european government government funding unavailable able collect amount customer result operation adversely affect plan supply viread truvada certain develop country access program expose unforeseen liability risk launch access program pursuant supply viread truvada cost develop country supply distribution drug resourcepoor environment complicated undertaking program develop face unforeseen challenge risk rise unforeseen liability example patient develop country viread truvada closely supervise doctor develop nation accordingly increase likelihood viread truvadarelate complication go undetected untreated result significant liability gilead product revenue reduce import country product available low price price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world reexporte european country resold high price happen product particularly viread truvada agree provide cost access program revenue adversely affect addition european union require permit cross border sale allow buyer country governmentapprove price product relatively high purchase product legally country sell low price additionally consumer able purchase product include hiv product internet pharmacy country substantial discount cross border sale adversely affect revenue country require grant compulsory license product face generic competition product number develop country government official group suggest pharmaceutical company drug hiv infection available low cost alternatively government country require grant compulsory license allow competitor table content manufacture sell version product reduce product sale certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread currently engage discussion brazilian government affordability hiv product addition concern cost availability tamiflu fear grow potential avian flu pandemic generate international discussion potential compulsory licensing tamiflu patent furthermore roche issue voluntary license permit party manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override gilead tamiflu patent roche issue additional voluntary license permit party manufacturing tamiflu development reduce royalty receive roche sale tamiflu certain country permit enforcement patent manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental party payor reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement government authority thirdparty payor increasingly challenge price medical product service particularly innovative new product therapy result low average sale price example majority sale ambisome vistide majority sale truvada viread hepsera subject reimbursement government agency result significant discount list price rebate obligation business adversely affect increase international pricing pressure pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement policy price general europe success viread truvada emtriva hepsera ambisome tamiflu depend largely obtain maintain government reimbursement european country include united kingdom france patient use prescription drug reimburse government addition negotiate price governmental authority delay commercialization month expect success product development particularly europe depend ability obtain reimbursement reimbursement available reimbursement policy adversely affect ability sell product profitable basis example europe international market government control price prescription pharmaceutical expect price prescription pharmaceutical decline life product volume increase new drug come market face significant price decrease product europe believe continue foreseeable future government struggle escalate health care spending result pricing practice difficult maintain historic level profitability achieve expect rate growth result operation adversely affect future health care reform united states foreign jurisdiction number legislative regulatory change healthcare system impact pricing product united states december president bush sign law new medicare prescription drug coverage legislation legislation authorize center medicare medicaid services cms agency department health human service administer medicare implement new medicare coverage benefit table content prescription drug prescription drug program begin january factor influence possible impact gilead drug class cover payment level new medicare program lower previous medicare payment medicare patient pay co insurance influence product recommend physicians select patient program enrollment mandatory dually eligible medicaid medicare assurance drug recognize new medicare program outpatient prescription drug pay level reflect current historical level federal medicare proposal state medicaid drug payment change healthcare reform lower payment product result operation materially adversely affect reimbursement change emerge medicare prescription drug coverage legislation extent private insurer blue cross blue shield manage care program follow medicaid coverage payment development adverse effect low medicare payment magnify private insurer adopt low payment additionally state enact health care reform legislation federal state development possible impact propose legislation reform unclear result pricing reimbursement restriction adversely impact revenue able obtain effective patent protect technology use competitor patent company require stop pay use require technology success depend significant degree ability obtain patent license patent right preserve trade secret operate infringe proprietary right number foreign patent patent application right patent relate compound product technology risk issue patent enforceable provide adequate protection pende patent application result issue patent patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete patent patent cover active ingredient ambisome addition patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera asia major market therapie hbv indication hepsera develop obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension addition certain country africa asia include china permit enforcement patent manufacturer able sell generic version product country competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive ultimately successful approval process product fda determine product grant exclusivity period manufacturer application approval generic version product grant generic manufacturer wait challenge patent protect product grant exclusivity year prior end exclusivity period time time receive notice manufacturer indicate intend import chemical intermediate possibly table content use make product possible generic manufacturer consider attempt seek fda approval similar identical drug abbreviate new drug application application form typically manufacturer seek approval generic drug patent subject challenge need spend significant resource defend challenge able defend patent successfully success depend large ability operate infringe patent proprietary right party infringe patent prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product addition use significant proprietary technology rely unpatented trade secret proprietary knowhow protect certain aspect production technology trade secret know independently discover competitor face significant liability result product cover insurance successful claim materially reduce earning testing manufacturing marketing use commercial product product development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company maintain product liability insurance successful product liability claim cover insurance require pay amount provide insurance impair financial condition ability clinically test market product expensive litigation reduce earning name defendant lawsuit use average wholesale price reimbursement rate medicaid name defendant lawsuit allege violation federal security law adverse result lawsuit result material damage significantly reduce earning cash flow change effective income tax rate reduce earning factor favorable unfavorable effect effective income tax rate factor include limited interpretation exist tax law adoption statement financial accounting standard revise sharebased payment sfas r relate accounting stock option sharebase payment change tax law rate future level research development spending change accounting standard future level capital expenditure change mix earning tax jurisdiction operate change overall level pretax earning impact income tax provision result abovementione factor significant negative impact result operation recently adopt change account stock option significantly reduce earning financial accounting standard board fasb recently issue sfas r require record additional compensation expense relate stock option equity incentive impact earning result new standard significant negative impact report result operation compare result report prior accounting standard stock option sharebase payment item b unresolved staff comment applicable table content item property primary facility locate foster city california house executive offices administrative research development activity location building lease building lease facility san dimas california house manufacturing warehousing research development activity addition lease facility durham north carolina house administrative research development activity outside united states lease facility cambridge area united kingdom house administrative sale marketing activity commercial medical administrative group previously base paris france relocate lease facility london area united kingdom lease facility dublin area ireland house manufacturing distribution facility partly partly lease space addition lease facility house sale marketing activity france spain portugal italy greece australia germany canada believe exist property include own lease site good condition suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet longterm growth need item legal proceeding information pertain legal proceeding find item note consolidated financial statement page annual report incorporate reference item submission matter vote security holder applicable table content ii item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq stock market symbol gild follow table set forth period indicate high low intraday sale price share common stock nasdaq stock market price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low quarter second quarter quarter fourth quarter quarter second quarter quarter fourth quarter september implement twoforone stock split form stock dividend share share amount period present restate reflect stock split february share common stock outstanding hold approximately stockholder record pay cash dividend common stock inception currently expect retain earning use operation expansion business anticipate pay cash dividend near future table content item select financial datum gilead sciences inc select consolidated financial datum thousand share datum year end december consolidated statement operation datum total revenue purchase inprocess research development note total cost expense income loss operation gain sale oncology asset note gain warrant note loss marketable security note provision benefit income taxis note income loss cumulative effect change accounting principle cumulative effect change accounting principle note net income loss amount common sharebasic income loss cumulative effect change accounting principle note cumulative effect change accounting principle note net income loss sharebasic note share share calculationbasic note amount common sharedilute income loss cumulative effect change accounting principle note cumulative effect change accounting principle note net income loss sharedilute note share share calculationdilute note table content gilead sciences inc select consolidated financial datacontinue december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm debt longterm obligation convertible debt retain earning accumulate deficit total stockholder equity note note gilead recognize million royalty revenue relate resolution dispute roche gilead record tax provision benefit million relate repatriation qualified foreign earning american job creation act gilead record gain million relate warrant purchase capital stock eyetech predecessor osi complete initial public offering gilead complete acquisition net asset triangle aggregate purchase price million approximately million purchase price allocate purchase inprocess research development record income tax benefit million relate reduction valuation allowance certain net defer tax asset sell share common stock osi recognize loss sale marketable security million share partial consideration sale oncology asset complete sale oncology asset relate technology osi record nonoperating gain million record nonoperate gain million sale equity interest proligo llc note adopt sfas nos collectively refer sfas accounting derivative instrument hedge activity quarter change account change accounting principle note february march september gilead implement twoforone stock split form stock dividend share share amount period present restate reflect stock split note cash dividend declare pay common stock table content item management discussion analysis financial condition result operation follow management discussion analysis mda intend help reader understand result operation financial condition gilead mda provide supplement read conjunction financial statement accompany note financial statement executive summary gilead experience year increase revenue profit cash flow successful launch adoption drug treatment human immunodeficiency virus hiv hepatitis b virus hbv maintenance product sale ambisome able increase market share favorable consistent safety efficacy profile demonstrate date product include viread truvada emtriva increase market share hiv product helped contribute increase hiv product sale billion continue adoption hepsera increase product sale million increase intend build success product continue engage longterm clinical study differentiate product additionally hiv franchise intend work patient physician key opinion leader educate benefit early treatment expect help expand treatedpatient population continue gather positive datum safety efficacy truvada launch european country believe uptake truvada continue drive force increase hiv product sale year focus create believe solid foundation longterm growth look opportunity acquire inlicense innovative technology drug candidate develop technology alongside inhouse initiative enter collaboration japan tobacco inc japan tobacco advance phase clinical trial base hiv integrase inhibitor license additionally demonstrate bioequivalence formulation fixeddose combination truvada bristolmyers squibb company bms sustiva triple product begin dose patient phase study hcv drug candidate license achillion pharmaceutical internally significant progress enrollment phase study compare efficacy safety tenofovir versus hepsera patient hbv file investigational new drug application december gs internal integrase clinical candidate initiate phase clinical study healthy volunteer february intend sustain longterm growth business continue discover commercialize new drug antiviral area especially hiv hepatitis c virus hcv area plan explore therapeutic area significant unmet medical need license acquisition opportunity fit core competency complement longterm growth strategy ability grow consist build strong global organization year relocate european commercial medical administrative headquarters france united kingdom unite function regulatory safety information technology group headquarter united kingdom strategic expansion global sale marketing activity revenue continue increase continue collection improvement certain european region year cash investment management continue important priority addition reexamine cash investment portfolio investment policy strategy cash collaborative activity quarter royalty pharma purchase royalty interest own emory university emtricitabine million furthermore december leverage strong financial position result enter million credit facility syndicate bank consist million term loan million revolve credit facility term loan facilitate onetime repatriation qualified foreign earning american job creation act ajca result million income tax benefit record draw amount revolve facility facility flexibility use table content fund future corporate development initiative include licensing opportunity potential acquisition allow meet ongoing work capital infrastructure need focus continue build current infrastructure continue advance drug candidate clinic execute operational goal promote product safety efficacy datum drive high patient adoption intend build strong working relationship f hoffmannla roche ltd roche respect tamiflu amend agreement jointly drive effective marketing supply chain strategy meet increase demand tamiflu focus significant resource prepare launch coformulate truvadasustiva product united states working merck co inc merck bms arrangement launch coformulate product outside united states finally continue strengthen global infrastructure well support grow employee customer base include expand certain aspect manufacturing capability upgrade facility information system critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate estimate include related revenue recognition allowance doubtful account inventory prepay royalty clinical trial accrual tax provision base estimate historical experience marketspecific assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement revenue recognition recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure record estimate reduction revenue expect return expire product distributor fee government rebate program medicaid reimbursement customer incentive cash discount prompt payment estimate distributor fee base contractually determine fix percentage sale estimate government rebate program cash discount base contractual term historical utilization rate expectation future utilization rate program estimate product return include new product base ongoing analysis industry historical return pattern include monitor feedback receive sale force customer use satisfaction review inventory datum available inventory management agreement wholesaler assist monitor channel inventory level purchase thirdparty datum monitor prescription new product compare product product similar sale channel monitor activity clinical trial key competitor assess potential impact future sale return expectation necessary expect return market drug generally low shelf live product united states range months truvada hepsera month viread ambisome condition competitive market serve drug circumstance change action increase product return estimate offer additional customer incentive result incremental reduction future revenue time return estimate change new incentive offer contract revenue research development rd record performance occur earning process complete base performance requirement contract nonrefundable contract fee performance obligation exist continue involvement gilead recognize early occur payment receive collection reasonably assure table content revenue nonrefundable upfront license fee milestone payment continue involvement development collaboration obligation supply product recognize performance occur obligation complete accordance specific term gilead obligation type arrangement revenue recognize obligation fulfil ratably development manufacturing period revenue associate substantive atrisk milestone recognize base achievement milestone define respective agreement advance payment receive excess amount earn classified defer revenue allowance doubtful account maintain allowance doubtful account estimate loss result inability customer require payment allowance base analysis factor include limited contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice financial condition customer economic environment operate deteriorate result inability payment additional allowance require allowance doubtful account balance percentage total account receivable materially change december december believe allowance doubtful account adequate cover anticipate loss current condition significant deterioration factor especially respect government funding reimbursement practice european market materially change expectation result increase allowance doubtful account inventory record write down value inventory base review historical quantity bad batch experience manufacturing process expectation production inventory level perform quality control review individual raw material batch generally record inventory writeoff relate estimate obsolescence risk competition primarily shelf life product long current assumption future production inventory level demand competition change actual market condition favorable project management additional inventory writedown require negatively impact product gross margin result operation prepay royalty capitalize royalty prepay cost specifically related emtricitabine royalty pay emory hiv indication base present value future royalty obligation expect pay emory assume certain expect level product sale incorporate emtricitabine technology net book value prepay asset determine good estimate relevant future product sale available time consummate transaction review annually expect future performance product indicator support writedown net recoverable value asset amortize prepay royalty base effective royalty rate derive forecast hiv product sale incorporate emtricitabine product sale forecast prepare annually determine good estimate future activity previously unanticipate significant change occur sale forecast include introduction compete product competitor hiv market emtricitabine prospectively update royalty rate amortize prepay royalty increase future royalty expense review royalty rate annually adjust rate base significant new fact circumstance arise clinical trial accrual record accrual estimate clinical study cost clinical study perform party contract research organization cro cost significant component rd expense table content incur cro cost million million million respectively accrue cost clinical study perform cro straightline basis service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro validate accrual quarterly vendor perform detailed review activity relate significant contract base result validation process assess appropriateness accrual adjustment deem necessary ensure expense reflect actual effort incur cro generally significant portion total clinical trial cost associate start activity trial patient enrollment gilead extensively outsource clinical trial activity usually perform small portion startup activity inhouse result cro typically perform total startup activity trial include document preparation site identification screen preparation prestudy visit training program management budget basis cost typically total contract value actual basis percentage range significantly wider contract expand reduced scope compare original budget startup cost particular trial change significantly startup cost usually occur month contract execute milestone event drive nature remain activity relate cost patient monitor administration generally occur ratably life individual contract study contract negotiate fix unit price vary length month single dose phase study year complex phase study average length contract upper end range order provide longterm safety efficacy datum support commercial launch viread truvada hepsera emtriva material cro contract terminable write notice gilead generally liable actual effort expend cro point time contract regardless payment status amount pay advance service perform refunded contract terminate december difference actual estimate activity level particular study significant require material adjustment management receive complete accurate information vendor underestimate activity level associate study give point time record additional potentially significant rd expense future period tax provision estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization portion defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination adjustment fourth quarter determine likely certain defer tax asset realized release related valuation allowance result income tax benefit approximately million million respectively similarly determine able realize defer tax asset valuation allowance increase valuation allowance period determination future effective income tax rate affect factor change tax law regulation andor rate change interpretation exist law regulation change international organization change overall level income tax management discuss development selection critical accounting policy audit committee gilead board director audit committee review disclosure present relate table content result operation total revenue total revenue billion billion million include total revenue product sale royalty revenue contract revenue include revenue earn manufacturing collaboration product sale product sale consist follow thousand change change hiv product viread truvada emtriva hiv product ambisome hepsera vistide daunoxome total product sale total product sale increase compare compare case primarily increase volume sale hiv product significant percentage product sale continue denominate foreign currency use forward contract hedge percentage forecast international sale primarily denominate euro reduce eliminate fluctuation sale change foreign currency exchange rate hiv product viread truvada emtriva approve sale united states october august july respectively viread truvada emtriva approve sale european union february february october respectively sale truvada commence united states quarter countryspecific launches europe begin hiv product volume increase compare compare hiv product volume growth united states respectively volume increase outside united states respectively viread sale viread remain relatively consistent sale level result continue strong performance viread offset impact patient switch vireadcontaine regimen contain truvada country truvada available sale viread increase compare primarily drive volume increase united states european country truvada sales truvada increase united states year truvada sale truvada patient come primarily patient new therapy secondarily patient switch regimen include contain viread emtriva table content emtriva sale emtriva decrease compare primarily drive impact patient switch emtrivacontaine regimen contain truvada country truvada available expect sale hiv product range billion billion include future product sale result triple product approve commercial sale united states predict triple product approve food drug administration fda ambisome ambisome product sale increase compare primarily drive increase overall sale volume partially offset low pricing region outside united states product sale increase prior year primarily high sale volume outside united states strong european currency partially offset low pricing region outside united states discussion ambisome product sale relate solely sale ambisome astellas pharma inc astellas successor fujisawa usa inc record manufacturing cost great manufacturing efficiency unit manufacturing cost ambisome decrease decrease revenue report sale astella royalty earn sale ambisome astella discuss royalty revenue result pricing pressure europe increase competition expect ambisome product sale range million million hepsera sale hepsera increase compare compare primarily drive sale volume growth europe united states volume increase respect sale hepsera glaxosmithkline gsk sell hepsera gsk manufacturing cost connection gsk distribution activity asia royalty earn sale hepsera gsk record royalty revenue expect hepsera sale range million million take account impact exist potential competitor product united states europe royalty revenue record royalty revenue million compare million million threeyear period significant source royalty revenue sale tamiflu roche sale ambisome united states astellas november gilead resolve dispute roche relate development license agreement agree terminate relate arbitration pende gilead roche term dispute resolution gilead roche establish joint committee oversee manufacture commercial pandemic planning product option copromote tamiflu specialized areas united states relate dispute resolution roche pay million recognize royalty revenue consist million relate dispute royalty million relate reimbursement contractual cost good adjustment previously reduce earn royalty million relate update royalty payable gilead month base current year royalty rate instead prior year effective royalty rate exclude amount receive connection dispute resolution significant year year increase tamiflu royalty primarily high royalty receive roche high tamiflu sale cause significant flu season particularly japan fulfillment order pandemic table content readiness supply certain country royalty revenue earn roche include amount recognize dispute resolution million million million respectively compare royalty revenue earn sale tamiflu roche increase substantially severe influenza epidemic united states late early increase awareness discussion supply influenza treatment increase roche sale tamiflu consequently royaltie difficult estimate party product sale similar outlicensing arrangement arrangement astella royalty record month arrear record royalty revenue roche quarter arrear royalty revenue earn sale ambisome astella remain consistent million slight increase million contract revenue total contract revenue million compare million million contract revenue consist primarily million milestone payment earn osi pharmaceuticals inc osi successor eyetech pharmaceuticals inc commercial sale macugen united states revenue earn contract manufacturing project contract revenue consist primarily million research milestone revenue earn osi include million recognize file new drug application osi europe united states macugen cost good sell product gross margin follow table indicate total product sale cost good sell thousand product gross margin change change total product sale cost good sell product gross margin product gross margin slightly low product mix change patient continue switch viread high margin product truvada product gross margin relatively consistent positive impact improvement certain manufacturing process favorable foreign currency environment offset change product sale mix result royalty pharma purchase royalty interest own emory emtricitabine july capitalize million prepay royalty represent share million purchase price quarter begin amortize prepay royalty cost good sell remain life underlie patent base effective royalty rate derive forecast sale record royalty royalty pharma base actual emtricitabine net sale relative royalty pharma ownership interest underlie emory royalty interest expect transaction favorable impact emtricitabine product gross margin longterm impact overall product gross margin significant expect product gross margin generally consistent exclude impact potential launch triple product predict triple product approve fda expect launch triple product decrease product gross margin percentage impact net profit fact majority owner table content joint venture bms consolidate triple product revenue earn product margin truvada portion triple product earn zero product margin sustiva portion triple product research development expense follow table summarize rd expense major component thousand change change research clinical development pharmaceutical development total rd expense consist primarily personnel cost include salary benefit clinical study perform cro material supply license fee overhead allocation consist support facility relate cost rd activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology cost clinical development cost include cost phase clinical trial pharmaceutical development cost consist product formulation chemical analysis cost million increase rd expense compare primarily attributable million payment emory connection amendment exist license agreement emory relate obligation develop emtricitabine hepatitis b indication million payment japan tobacco relate execution hiv integrase license agreement gs increase salary additional headcount million increase clinical product development activity associate hcv hbv hiv program payment emory japan tobacco expense underlie technology incomplete alternative future use case emory significant rd activity expect year million increase rd expense compare primarily attributable increase salary million largely high headcount million research license fee pay relation hcv collaboration agreement enter achillion pharmaceutical achillion genelabs technologies genelabs increase cro cost million associate increase clinical activity payment achillion genelab expense underlie technology alternative future use increase rd expense compare partially offset decrease spending discontinuation internal program gs gs focus development certain hiv investigational product rd expense include reimbursement gilead million settlement contractual dispute vendor expect rd expense increase level reflect increase spending internal collaborative rd effort relate expectation pipeline product progress advanced clinical trial increase headcount impact expense sharebase payment sell general administrative expense follow table summarize sga expense thousand change change sell general administrative table content sga expense million increase million compare significant increase primarily increase salarie million largely high headcount increase market research speaker program symposia cost million million severance relocation expense associate relocation european commercial medical administrative headquarters france united kingdom increase medical education cost million increase journal advertising cost million general expansion sale marketing activity worldwide increase partially offset decrease bad debt expense million result high collection certain european country sga expense million compare million include reclassification phase clinical trial expense rd mention significant increase expense compare primarily relate increase salarie million largely high headcount increase consulting fee million relate sarbanesoxley compliance business strategy consulting increase cost million relate speaker program grant journal advertising remainder increase sga expense compare generally increase global marketing effort expand infrastructure require support growth business infrastructure investment implement reorganization sale marketing function newly create commercial division conjunction reorganization create fill new position executive vicepresident commercial operation responsible global commercial operation strategy product portfolio expect sga expense increase primarily anticipate cost associate launch support truvada country cost related ongoing investment global commercial organization hire promotional program impact expensing share base payment purchase inprocess research development connection acquisition net asset triangle pharmaceuticals inc triangle complete january record purchase inprocess rd expense million quarter charge triangle incomplete rd program reach technological feasibility alternative future use acquisition date value purchase inprocess rd determine estimate related future net cash flow present value risk adjust discount rate discount rate significant assumption base estimate weighted average cost capital adjust upward risk associate project acquire project cash flow acquire project base estimate revenue operate profit relate project consider stage development potential product acquire time resource need complete development approval product life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound include obtain fda regulatory approval risk relate viability potential alternative treatment future target market table content summary program acquisition date follows update subsequent change status development estimate acquisition date fair value program description status development millions emtricitabine hiv nucleoside analogue phase study complete prior show inhibitor hiv acquisition date marketing approval receive replication patient fda july emtriva european union approval receive european commission october emtricitabinetenofovir df fixed dose fixeddose coformulation tenofovir acquisition date work combination hiv therapy emtricitabine commence potential coformulation extent work emtricitabine single agent progress march application marketing approval submit united states european union august marketing approval united states receive fda truvada fixeddose coformulation tenofovir emtricitabine marketing approval european union receive february sale commence later quarter amdoxovir hiv purine dioxolane nucleoside program phase trial acquisition offer advantage market date terminate licensing agreement nucleoside activity emory university university drug resistant virus georgia research foundation inc exhibit patient hiv infection development discontinue clevudine hbv pyrimidine nucleoside analogue program phase trial acquisition show inhibitor date august licensing agreement hbv replication patient chronically bukwang pharm ind co ltd terminate infected hbv development discontinue emtricitabine hbv inhibitor hbv replication program phase trial acquisition patient chronically infect hbv date complete december continue evaluate strategy development emtricitabine hepatitis b indication currently expect undertake significant rd activity year table content asset impairment record asset impairment charge million certain longlived asset primarily leasehold improvement manufacture laboratory equipment noncash charge drive decision december terminate liposomal rd activity san dimas discontinue daunoxome product line impairment base analysis undiscounte cash flow generate affected asset compare carry value carrying value exceed related estimate undiscounted cash flow write carry value longlive asset estimate fair value subsequent decision discontinue daunoxome product line receive unanticipated request europe ask gilead reconsider sell daunoxome result request management decide continue sell product certain country evaluate supply sale strategy respect daunoxome accordance generally accept accounting principle new cost basis impair asset adjust new fact circumstance gain warrant pursuant agreement eyetech pharmaceuticals inc eyetech predecessor osi enter march receive warrant purchase share eyetech series b convertible prefer stock exercisable price share january eyetech complete initial public offering common stock time adjust fair value warrant result gain million time fair value warrant estimate blackschole valuation model volatility rate discount rate end quarter exercise warrant net basis share eyetech common stock consideration exercise price subsequently hold share eyetech common stock second quarter sell eyetech share own realize gain approximately million include interest income net makewhole payment convertible debt redemption october call redemption outstanding convertible senior note december november convertible senior note call provisional redemption base market price gilead common stock exceed certain threshold aggregate principal outstanding note million convertible senior note redeemable redemption price equal principal note plus cash payment equal accrue unpaid interest redemption date cash makewhole payment equal principal value note interest actually pay accrue unpaid date issuance note redemption date interest convertible senior note cease accrue redemption date remain right holder receive redemption payment include accrue unpaid interest redemption date makewhole payment alternatively note holder elect convert note share gilead common stock price share share gilead common stock principal note holder substantially outstanding note convert note share gilead common stock prior november redemption date result conversion share common stock issue note holder connection redemption aggregate makewhole payment million note holder interest income net record interest income net million million million increase primarily attributable high cash balance previous year interest income depend principally prevail interest rate level cash cash equivalent marketable security balance table content interest expense incur interest expense million compare million million decrease primarily attributable conversion million convertible senior note share common stock november decrease primarily conversion million convertible subordinate note share common stock december expect interest expense increase result interest pay million fiveyear term loan enter december minority interest joint venture minority interest reflect bmss interest operating result joint venture bms united states operation joint venture commence activity primarily focus triple product achieve bioequivalence coformulation achievement successful formulation fourth quarter expect significant increase activity especially fda commercial approval obtain provision benefit income taxis provision benefit income taxis million million million respectively effective income tax rate differ federal statutory rate generally recognition previously unbenefitte net operating loss tax credit carryforward certain earning operation jurisdiction low tax rate united states jurisdiction taxis provide earning plan reinveste indefinitely outside united states benefit derive qualifying dividend american job creation act ajca partially offset state taxis october ajca sign law ajca allow deduction certain qualified foreign earning repatriate define ajca elect apply provision qualify earning repatriate earning repatriation result onetime tax provision benefit approximately million include reversal defer tax liability previously accrue unremitted foreign earning million december effective income tax rate differ federal statutory rate generally recognition previously unbenefitte net operating loss tax credit carryforward certain earning operation jurisdiction low tax rate united states jurisdiction taxis provide earning plan reinveste indefinitely outside united states partially offset state taxis tax benefit include reversal valuation allowance certain defer tax asset december conclude likely realize portion benefit relate defer tax asset accordingly reduce valuation allowance asset record tax benefit million recognition defer tax asset impact cash flow partially offset record tax benefit income tax expense associate income earn foreign subsidiary foreign loss low tax rate nontax deductibility purchase inprocess rd significant net operating loss carryforward reduce tax liability exclude benefit relate reversal valuation allowance write purchase inprocess rd effective tax rate table content liquidity capital resource follow table summarize cash cash equivalent marketable security work capital statement cash flow thousand december cash cash equivalent marketable security working capital year end december cash provide operating activity invest activity financing activity cash cash equivalent marketable security cash cash equivalent marketable security total billion december increase december cash cash equivalent marketable security total billion december increase december increase billion million primarily net cash provide operation million million proceed issuance stock employee stock plan million million proceed issuance longterm debt million increase partially offset capital expenditure million million work capital work capital december billion compare billion december significant factor result increase work capital billion increase cash cash equivalent marketable security million increase account receivable primarily increase sale partially offset improve collection activity especially certain european country collection traditionally slow million increase inventory meet grow demand hiv product hepsera meet gilead access program requirement million increase defer tax asset million increase prepaid current asset primarily relate current portion prepay royalty emory emtricitabine increase partially offset million increase income taxis payable primarily high profitability partially offset tax benefit employee stock plan million increase reflect current portion million term loan enter december table content million increase accrue liability include increase accrual relate medicaid rebate royalty expense sale marketing expense rent expense partially offset decrease liability associate fair value forward currency contract dollar strengthen euro work capital december billion compare billion december significant factor result increase work capital million increase cash cash equivalent marketable security million increase account receivable primarily increase sale viread united states europe sale new product truvada launch united states half million increase inventory primarily increase purchase raw material production viread truvada inventory meet increase sale demand increase work capital partially offset million decrease current defer tax asset primarily utilization net operating loss tax credit carryforward offset taxable income million increase current liability include million increase medicaid rebate obligation million increase defer revenue primarily royalty receive roche million increase liability associate fair value forward currency contract dollar continue weaken euro million increase account payable primarily increase raw material purchase support viread truvada sale growth cash provide operating activity cash provide operating activity primarily drive increase net income expect continue primary recur source cash increase cash provide operating activity year end december million primarily attribute product sale growth increase cash collection customer payment receive related resolution dispute roche partially offset million prepay royalty emory cash investing activity cash investing activity primarily relate purchase sale maturity availableforsale security capital expenditure million cash investing activity compare million million increase cash investing activity primarily increase cash cash equivalent balance year year net cash investing activity purchase availableforsale security increase million compare million million cash investing activity higher compare million pay acquisition triangle net asset million pay purchase foster city facility capital expenditure related primarily expand certain aspect manufacturing capability upgrade facility capital expenditure primarily facility improvement include approximately million associate completion pilot plant foster city develop drug process prepare material supply clinical trial additional spending laboratory manufacturing equipment accommodate growth table content cash provide financing activity cash provide financing activity primarily relate proceed million term loan stock option exercise stock purchase employee stock plan receive million million million respectively relate stock option exercise stock purchase employee stock purchase plan believe exist capital resource supplement cash generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include commercial performance current future product progress scope rd effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability administrative expense possibility acquire manufacturing capability additional office facility possibility acquire company new product establishment additional collaborative relationship company defense cost associate settlement adverse result litigation future require additional funding form proceed equity debt financing universal shelf registration statement file december potential issuance million security funding require assure available favorable term december enter agreement syndicate bank provide fiveyear million senior credit facility million facility comprise uncollateralized million term loan uncollateralize million revolve credit facility proceed term loan december facilitate qualified intercompany cash dividend distribution million gilead biopharmaceutics ireland corporation gbic whollyowne irish subsidiary gilead parent company gilead sciences inc repatriation qualified foreign earning provision ajca term million term loan minimum principal payment repay end calendar quarter begin march million december amount outstanding million revolve credit facility capacity revolve credit facility increase maximum million million term loan repay ability irrevocably cancel unutilized portion revolve credit facility offbalance sheet arrangement offbalance sheet arrangement currently material reasonably likely material financial position result operation contractual obligation contractual obligation consist capital operating lease purchase obligation primarily form capital commitment purchase obligation active pharmaceutical ingredient inventoryrelate item clinical trial contract follow table summarize enforceable legally bind obligation future commitment obligation relate contract likely continue regardless table content fact cancelable december follow table summarize contractual obligation december thousands payment period contractual obligation total year year year year term loan capital lease obligation operating lease obligation capital commitment purchase obligation clinical trial total december longterm debt consist million year term loan enter fourth quarter december firm capital project commitment approximately million relate facility improvement addition budget significant capital expenditure mainly anticipate increase infrastructure need high rd spending capital spend future year december firm commitment purchase active pharmaceutical ingredient inventoryrelate item amount disclose represent minimum purchase requirement actual purchase expect significantly exceed amount december clinical study clinical trial phase significant clinical trial expenditure cro contract cro cancelable generally cancel contract amount reflect commitment base exist contract reflect future modification exist contract anticipate potential new contract recent accounting pronouncement december fasb issue sfas revise sharebased payment sfas r revision sfas sfas r supersede accounting principle board opinion apb amends sfas statement cash flow sfas r require sharebase payment employee director include grant stock option recognize income statement base fair value begin quarterly period june early adoption permit april securities exchange commission adopt new rule amend compliance date sfas r allow adopt new standard effective january pro forma disclosure previously permit sfas long alternative financial statement recognition sfas r adopt sfas r january sfas r determine appropriate fair value model relate assumption value sharebased payment amortization method compensation cost transition method date adoption transition method include modify prospective retroactive adoption method modify prospective method require compensation expense record unvested stock option restrict stock begin quarter adoption sfas r retroactive method record compensation expense unvested stock option restrict stock begin period restate determined adopt modify prospective method continue use black schole option valuation model base preliminary analysis expect adoption sfas r material impact income statement earning share currently estimate impact approximately diluted share sfas r require benefit tax deduction excess recognize compensation cost report statement cash flow finance cash flow operate cash flow require current accounting literature requirement reduce net operating cash flow increase net financing cash flow period adoption table content item quantitative qualitative disclosure market risk foreign currency exchange risk operation include manufacture sale activity united states sale activity country outside united states include europe australia result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change exchange rate dollar foreign currency significant euro british pound australian dollar dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business enter foreign exchange forward contract mitigate impact change currency exchange rate cash flow sale denominate foreign currency foreign currencydenominate net monetary asset liabilitie significant percentage product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar return sale negatively impact financial condition use forward contract hedge percentage forecast international sale primarily denominate euro currency recent year foreign currency exchange fluctuation positively negatively impact product sale gross margin impact foreign currency fluctuation moderated hedge program follow table summarize notional amount average currency exchange rate fair value open foreign exchange forward contract december contract maturity year average rate state term foreign currency dollar fair value represent estimate settlement amount december notional amount fair value dollar thousand currency notional average rate fair value british pound euro australian dollar total total notional million fair value million open foreign exchange forward contract december compare total notional million fair value million open foreign exchange forward contract december significant increase notional outstanding contract primarily attribute project increase product sale forecast period interest rate risk portfolio availableforsale investment security variablerate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base duration industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk table content liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestgenerate asset interestbeare liability december dollar thousand year end december total fair value december asset availableforsale security average interest rate liability longterm debt include current portion average interest rate longterm obligation include current portion average interest rate longterm debt consist million year term loan enter fourth quarter average interest rate base imply forward rate yield curve reporting date term loan minimum principal repay end calendar quarter begin march million interest accrue rate libor plus tiere contractual rate basis point prepay term loan time accrue interest prepay principal penalty premium outstanding interest principal december payable demand longterm obligation consist capital lease operating lease net noncancelable sublease interest portion payment include international credit risk account receivable balance december million compare million december growth account receivable balance primarily high product sale viread truvada united states europe certain country payment typically slow primarily greece italy portugal spain account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase credit risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding december past account receivable greece italy portugal spain total million million day past base contractual term receivables date experience significant loss respect collection account receivable believe substantially account receivable balance collectible perform credit evaluation customer financial condition generally require collateral item financial statement supplementary datum financial statement require item set forth begin report incorporate reference table content item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness design operation disclosure control procedure define sec rule control procedure company design ensure information require disclose company report file securities exchange act exchange act record process summarize report require time period base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective b management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define security exchange act rule af internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission coso base evaluation conclude internal control financial reporting effective december independent register public accounting firm ernst young llp audit consolidated financial statement include annual report issue report management assessment internal control financial reporting effectiveness internal control financial reporting december report audit internal control financial reporting appear table content report independent register public accounting firm board director stockholder gilead sciences inc audit management assessment include accompany management report internal control financial reporting include item gilead sciences inc maintain effective internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission coso criterion gilead sciences incs management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion management assessment opinion effectiveness gilead sciences inc internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting evaluate management assessment testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion management assessment gilead sciences inc maintain effective internal control financial reporting december fairly state material respect base coso criterion opinion gilead sciences inc maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states consolidated balance sheet gilead sciences inc december relate consolidated statement operation stockholder equity cash flow year period end december relate financial statement schedule report date february express unqualified opinion thereon ernst young llp palo alto california february table content c change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting item b information applicable iii item director executive officer registrant information require item concern director executive officer incorporate reference section definitive proxy statement file sec pursuant regulation connection annual meeting stockholder proxy statement headings nominee executive officer compliance section security exchange act gilead write code ethic apply director employee include executive officer code ethic available gilead website httpwwwinvestorsgileadcom corporate governance change waiver code ethic disclose website item executive compensation information require item incorporate reference section proxy statement heading compensation executive officer report compensation committee executive compensation compensation committee interlock insider participation performance measurement comparison item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference section proxy statement head security ownership certain beneficial owner management item certain relationship relate transaction information require item incorporate reference section proxy statement heading certain relationship relate party transaction compensation executive officer item principal accounting fee service information require item incorporate reference section proxy statement head principal accounting fee service table content iv item exhibit financial statement schedule follow document file annual report index list financial statement report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement schedule ii include report schedule omit require require information include financial statement note thereto exhibit follow exhibit file herewith incorporate reference exhibit exhibit footnote number description document asset purchase agreement registrant osi pharmaceuticals inc date november agreement plan merger registrant simbolo acquisition sub inc whollyowne subsidiary registrant triangle pharmaceutical inc date december restate certificate incorporation registrant amend bylaw registrant amend restate march reference exhibit exhibit amend restate right agreement date october registrant chasemellon shareholder services llc amendment amend restate right agreement date october registrant mellon investor service llc know chasemellon shareholder services llc form indemnity agreement enter registrant director executive officer form employee proprietary information invention agreement enter registrant certain officer key employee form option agreement stock option plan letter agreement date september registrant iocbrega registrant employee stock purchase plan amend july registrant stock option plan amend restate april amend january amend january relate agreement registrant nonemployee director stock option plan amend january amend january include form option agreement thereunder amendment agreement date october registrant iocbrega table content exhibit exhibit footnote number description document amendment agreement date december registrant iocbrega development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc date september nexstar pharmaceutical incs incentive stock plan adopt february amend nexstar pharmaceutical inc director option plan adopt july lease date february registrant majestic mapa property llc lease date february registrant majestic mapa property llc lease date july registrant majestic realty co majesticmapa property llc amendment thereto date march agreement astellas pharma inc successor fujisawa usa inc registrant successor vestar inc date august amendment thereto date amendment agreement astellas pharma inc successor fujisawa usa inc registrant successor vestar inc april amendment agreement astellas pharma inc successor fujisawa usa inc registrant date march license distribution agreement date september dainippon sumitomo pharma co ltd successor sumitomo pharmaceuticals co ltd registrant successor nexstar pharmaceuticals inc settlement agreement date august registrant successor nexstar pharmaceuticals inc astellas pharma inc successor fujisawa usa inc liposome company inc amendment date april sumitomo pharmaceutical co ltd registrant successor nexstar pharmaceuticals inc license distribution agreement date september sumitomo registrant successor nexstar pharmaceuticals inc corporate plan retirement select planbasic plan document corporate plan retirement select planadoption agreement addendum gilead sciences inc defer compensation plan licensing agreement date april gilead world market limited glaxo group limit triangle pharmaceuticals inc stock incentive plan exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university date settlement agreement registrant successor triangle pharmaceuticals inc emory university dr david w barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited date settlement exclusive license agreement registrant successor triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation date august gilead sciences inc severance plan amend table content exhibit exhibit footnote number description document lease agreement date june th registrant gra associates limited llc premise locate university drive durham north carolina master clinical commercial supply agreement date january gilead world market ltd registrant patheon inc licensing agreement date march amend december april registrant osi pharmaceuticals inc successor eyetech pharmaceuticals inc amendment licensing agreement date eyetech pharmaceuticals inc registrant amendment licensing agreement date december osi pharmaceuticals inc successor eyetech pharmaceuticals inc registrant amendment licensing agreement date august osi pharmaceuticals inc successor eyetech pharmaceuticals inc registrant amendment date license agreement date april glaxo group limited gilead world market limited amendment date january licensing agreement date april glaxo group limited gilead world market limited employment agreement date april registrant mark l perry gilead sciences inc equity incentive plan amend collaboration agreement registrant gilead holding llc bristolmyers squibb company er squibb son llc bristolmyers squibb gilead sciences llc date december license agreement japan tobacco inc registrant date march tenofovir disoproxil fumarate manufacturing supply agreement gilead world markets ltd pharmachem technologies grand bahama ltd date july royalty sale agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july amend restate license agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july term loan agreement gilead biopharmaceutics ireland corporation lenders party thereto bank america na administrative agent date december parent guaranty agreement registrant date december subsidiary guaranty agreement date december gilead vintage park llc credit agreement registrant lender party thereto bank america na administrative agent swing line lender lc issuer date december subsidiary guaranty agreement gilead vintage park llc date december base salary name executive officer form employee stock option agreement equity incentive plan table content exhibit exhibit footnote number description document form nonemployee stock option agreement equity incentive plan corporate bonus plan code section bonus plan amendment supplement date november development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc date september restate amend toll manufacturing agreement gilead science limited registrant altana pharma oranienburg gmbh date november subsidiaries gilead sciences inc consent independent register public accounting firm power attorney reference signature section certification section certification section certification file exhibit registrant current report form k file january incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant registration statement form file july incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit registrant annual report fiscal year end march incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit nexstar pharmaceutical inc quarterly report form q quarter end june incorporate reference file exhibit nexstar pharmaceutical inc form q quarter end september incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit nexstar pharmaceutical inc fiscal year end december incorporate reference table content file exhibit nexstar pharmaceutical inc form q quarter end march incorporate reference file exhibit nexstar pharmaceutical inc fiscal year end december incorporate reference file exhibit nexstar pharmaceutical inc fiscal year end december incorporate reference file exhibit nexstar pharmaceutical inc form q quarter end september incorporate reference file exhibit nexstar pharmaceutical inc form q quarter end june incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit triangle pharmaceutical inc quarterly report form q quarter end september incorporate reference file exhibit triangle pharmaceutical inc current report form k file september incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit registrant definitive proxy statement file pursuant regulation connection registrant annual meeting stockholder incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant form q quarter end march incorporate reference file exhibit registrant form q quarter end september incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant current report form k file january incorporate reference file exhibit registrant current report form k file february incorporate reference management contract compensatory plan arrangement require file pursuant item b certain confidential portion exhibit omit mean mark portion asterisk mark exhibit file separately secretary sec mark pursuant registrant application request confidential treatment rule b securities exchange act table content gilead sciences inc consolidated financial statement year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement table content report independent register public accounting firm board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement operation stockholder equity cash flow year period end december audits include financial statement schedule list index item financial statement schedule responsibility management gilead sciences inc responsibility express opinion financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity generally accept accounting principle opinion relate financial statement schedule consider relation basic financial statement take present fairly material respect information set forth audit accordance standard public company accounting oversight board united states effectiveness gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion thereon ernst young llp palo alto california february table content gilead sciences inc consolidated balance sheet thousand share amount december asset current asset cash cash equivalent marketable security account receivable net allowance december december inventory defer tax asset prepay expense current asset total current asset property plant equipment net noncurrent portion prepay royalty noncurrent defer tax asset noncurrent asset liability stockholder equity current liability account payable accrue clinical preclinical expense accrue compensation employee benefit income taxis payable accrue liability defer revenue current maturity longterm debt longterm obligation year total current liability longterm defer revenue longterm debt longterm obligation year minority interest joint venture commitment contingency stockholder equity prefer stock par value share share authorize outstanding common stock par value share share authorize share issue outstanding december respectively additional paidin capital accumulate comprehensive income loss defer stock compensation retain earning accumulate deficit total stockholder equity accompany note table content gilead sciences inc consolidated statement operation thousand share amount year end december revenue product sale royalty revenue contract revenue total revenue cost expense cost good sell research development sell general administrative purchase inprocess research development asset impairment total cost expense income loss operation gain warrant makewhole payment convertible debt redemption interest income net interest expense minority interest joint venture income loss provision benefit income taxis provision benefit income taxis net income loss net income loss sharebasic share share calculationbasic net income loss sharedilute share share calculationdilute accompany note table content gilead sciences inc consolidated statement stockholder equity thousand common stock accumulate retain additional comprehensive earning total paidin income defer stock accumulate stockholder share capital loss compensation deficit equity balance december net loss unrealize loss availableforsale security net tax foreign currency translation adjustment unrealize loss cash flow hedge net tax comprehensive loss conversion convertible subordinate debt net acquisition triangle pharmaceuticals inc issuance employee stock purchase plan stock option exercise net tax benefit employee stock plan amortization defer stock compensation compensatory stock transaction balance december net income unrealize loss availableforsale security net tax foreign currency translation adjustment unrealize loss cash flow hedge net tax comprehensive income conversion convertible senior note net debt issuance cost issuance employee stock purchase plan stock option exercise net tax benefit employee stock plan amortization defer stock compensation compensatory stock transaction balance december net income unrealize loss availableforsale security net tax foreign currency translation adjustment unrealize gain cash flow hedge net tax comprehensive income issuance employee stock purchase plan stock option exercise net tax benefit employee stock plan amortization defer stock compensation compensatory stock transaction balance december accompany note table content gilead sciences inc consolidated statement cash flow thousands year end december operating activity net income loss adjustment reconcile net income loss net cash provide operating activity depreciation amortization purchase inprocess research development asset impairment loss disposal property plant equipment gain warrant defer tax asset tax benefit employee stock plan minority interest joint venture noncash transaction change operate asset liability account receivable net inventory prepay royalty prepay expense asset account payable income taxis payable accrue liability defer revenue net cash provide operating activity invest activity purchase marketable security proceed sale marketable security proceed maturitie marketable security acquisition triangle net asset net cash acquire acquisition real estate capital expenditure net cash investing activity financing activity proceed issuance common stock proceed longterm debt debt issuance cost repayment longterm debt net cash provide financing activity effect exchange rate change cash net increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year supplemental disclosure cash flow information interest pay income taxis pay noncash investing financing activity common stock issue conversion debt reclassification defer debt issuance cost additional paidin capital conversion debt accompany note table content gilead sciences inc note consolidated financial statement december organization summary significant accounting policy overview gilead sciences inc gilead company incorporate delaware june biopharmaceutical company discover develop commercialize therapeutic advance care patient suffer lifethreatening disease multinational company revenue approve product marketing operation country focus research clinical program antiinfective currently market viread tenofovir disoproxil fumarate emtriva emtricitabine truvada emtricitabine tenofovir disoproxil fumarate treatment human immunodeficiency virus hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection treatment fungal infection vistide cidofovir injection treatment cytomegalovirus cmv infection f hoffmanla roche ltd roche market tamiflu oseltamivir phosphate treatment influenza royalty pay collaborative agreement manufacture macugen pegaptamib sodium injection manufacturing agreement osi pharmaceuticals inc osi successor eyetech pharmaceuticals inc sell macugen treatment neovascular agerelate macular degeneration royalty pay collaborative agreement accompany consolidated financial statement include account company wholly own subsidiary joint venture bristol myers squibb company bms gilead primary beneficiary determine financial accounting standard board fasb interpretation consolidation variable interest entity fin r record minority interest consolidate financial statement reflect bmss interest joint venture significant intercompany transaction eliminate certain prior year amount reclassify consistent current year presentation additionally reclassify million variable rate demand obligation cash cash equivalent availableforsale marketable security previously report consolidated balance sheet consolidate statement cash flow include quarterly report form q september reclassification base interpretation cash equivalent pursuant statement financial accounting standard sfas statement cash flow sfas reclassification effect increase invest cash outflow purchase marketable security million increase invest cash inflow sale marketable security million month end september stock split september gilead complete twoforone stock split effect form stock dividend stockholder record august accordingly share share amount period present reflect stock split significant accounting policy estimate judgment preparation consolidated financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis management evaluate estimate include related revenue recognition allowance doubtful account inventory prepay royalty clinical trial accrual tax provision base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate table content gilead sciences inc note consolidated financial statementscontinue december revenue recognition recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure provide customer general right product return accept return product united states expire year expiration product deem damage defective receive customer recognition revenue product sale provision estimate future return product expire government reimbursement certain distributor fee customer incentive cash discount prompt payment estimate government reimbursement cash discount base contractual term expectation utilization rate program estimate distributor fee base contractual term estimate product return include new product base ongoing analysis industry historical return pattern party datum assist monitor channel inventory level subsequent prescription contract revenue research development rd record performance occur earning process complete base performance requirement contract nonrefundable fee performance obligation exist continue involvement gilead recognize early payment receive collection reasonably assure revenue nonrefundable upfront license fee milestone payment continue involvement development collaboration obligation supply product recognize performance occur obligation complete accordance specific term gilead obligation type arrangement revenue recognize manufacturing obligation fulfil ratably development manufacturing period revenue associate substantive atrisk milestone recognize base achievement milestone define respective agreement advance payment receive excess amount earn classified defer revenue royalty revenue sale ambisome recognize month follow correspond sale occur royalty revenue sale product recognize receive quarter follow quarter correspond sale occur shipping handle cost shipping handling cost incur inventory purchase product shipment record cost good sell consolidated statement operation research development expense major component rd expense consist personnel cost include salary benefit clinical study perform clinical research organization cro material supply license fee overhead allocation consist administrative facility relate cost rd activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology cost clinical development cost include cost phase clinical trial pharmaceutical development cost consist expense incur product formulation chemical analysis charge rd cost include clinical study cost expense incur consistent sfas accounting research development cost cost significant component rd table content gilead sciences inc note consolidated financial statementscontinue december expense clinical study perform party cro accrue cost clinical study perform cro straightline basis service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro monitor level performance significant contract include extent patient enrollment activity communication cro adjust estimate require quarterly basis expense reflect actual effort expend cro material cro contract terminable write notice gilead generally liable actual effort expend cro point time contract regardless payment status amount pay advance service perform refunded contract terminate contract include additional termination payment payable gilead terminate contract additional termination payment record contract terminate advertising expense expense cost advertising include promotional expense incur advertising expense million million million earning loss share basic earning loss share calculate base weightedaverage number common share outstanding year dilute earning loss share calculate base weightedaverage number common share dilutive security outstanding dilutive potential common share result assume exercise outstanding stock option equivalent determine base treasury stock method dilutive potential common share result assumed conversion convertible note determine base ifconverted method follow table reconciliation numerator denominator calculation basic diluted earning loss share thousands year end december numerator net income loss calculation basic earning loss share interest expense makewhole payment convertible note redemption net income loss calculation dilute earning loss share denominator weightedaverage common share outstanding calculation basic earning loss share effect dilutive security stock option equivalent convertible note weightedaverage common share outstanding calculation dilute earning loss share table content gilead sciences inc note consolidated financial statementscontinue december option purchase approximately million million share common stock outstanding year end december respectively option include computation dilute earning share option exercise price great average market price common stock period effect antidilutive diluted net loss share exclude prorate effect million convertible subordinated note convert approximately million share effect million convertible senior note convert approximately million share outstanding stock option equivalent purchase million share effect antidilutive stockbase compensation accordance provision sfas accounting stockbase compensation amend sfas accounting stockbase compensationtransition disclosure collectively sfas elect continue follow accounting principle board opinion apb accounting stock issue employee fasb interpretation account certain transaction involve stock compensationan interpretation apb opinion collectively apb accounting employee stockbase plan apb exercise price gilead employee director stock option equal exceed fair value underlie stock date grant compensation expense recognize table present net income loss basic diluted net income loss share compensation cost gilead nexstar pharmaceuticals inc triangle pharmaceuticals inc triangle stock option plan gilead employee stock purchase plan espp determine base estimate fair value award plan grant purchase date accordance sfa thousand share amount year end december net income lossa report add stockbased employee compensation expense include report net income loss net relate tax effect deduct total stockbase employee compensation expense determine fair value base method award net relate tax effect net income loss calculation basicpro forma earning loss share interest expense makewhole payment convertible debt redemption net income loss calculation dilutedpro forma earning loss share net income loss share basica report basicpro forma diluteda report dilutedpro forma table content gilead sciences inc note consolidated financial statementscontinue december fair value award grant stock option plan espp estimate grant purchase date blackschole option valuation model recognize accelerated expense attribution method refine volatility assumption arrive fair value begin fourth quarter purpose calculate expect volatility rate use time period well reflect current stage development length time public company drug approval enable achieve positive cash flow operation recent fouryear threeyear period respectively purpose calculate expect volatility twoyear time period derive weight average volatility fourth quarter weight average volatility quarter refinement assumption determine fair value stock option future generate fair value differ calculate base current model assumption calculate estimate fair value award multiple option approach follow assumption year end december expect life year stock option vest date espp purchase date discount rate stock option espp volatility expect dividend yield weight average estimate fair value espp share purchase pro forma disclosure present table currently permit sfas long alternative financial statement recognition sfas revise sharebased payment sfas r revision sfas adopt january december fasb issue sfas r supersede apb amends sfas sfas r require sharebase payment employee director include grant stock option recognize income statement base fair value begin quarterly period june early adoption permit sfas r determine appropriate fair value model relate assumption value sharebased payment amortization method compensation cost transition method date adoption transition method include modify prospective retroactive adoption method modify prospective method require compensation expense record unvested stock option restrict stock begin quarter adoption sfas r retroactive method require record compensation expense unvested stock option restrict stock begin period restate sfas r require benefit tax deduction excess recognize compensation cost report statement cash flow finance cash flow operate cash flow require current literature requirement reduce net operating cash flow increase net financing cash flow period adoption determine adopt modify prospective method continue use blackschole option valuation model base preliminary analysis expect adoption sfas r table content gilead sciences inc note consolidated financial statementscontinue december material impact income statement earning share currently estimate impact approximately share estimate future sharebase compensation expense affect stock price number stockbase awards board director grant number complex subjective valuation assumption relate tax effect valuation assumption include limited volatility stock price employee stock option exercise behavior cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent enter overnight repurchase agreement repos purchase security obligation resell follow day security purchase agreement resell record face value report cash cash equivalent investment policy enter repos major bank authorize dealer provide repos collateralize government security fair value fair value security sell gilead eligible instrument investment policy include cash equivalent include commercial paper money market fund bank obligation marketable nonmarketable security determine appropriate classification marketable security consist solely debt security include auction rate security variable rate demand obligation time purchase reevaluate designation balance sheet date marketable security consider availableforsale carry estimate fair value report cash equivalent marketable security unrealize gain loss availablefor sale security exclude earning report separate component stockholder equity interest income net include interest dividend amortization purchase premium discount realize gain loss sale security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value review include consideration cause impairment include creditworthiness security issuer number security unrealize loss position severity duration unrealize loss determine decline fair value investment accounting basis otherthantemporary reduce carry value security hold record loss decline reduction require past year result enter collaboration time time gilead hold investment nonpublic company record nonmarketable security cost noncurrent asset amount otherthantemporary impairment regularly review investment indicator impairment investment nonmarketable security material period present concentration risk subject credit risk portfolio cash equivalent marketable security policy limit amount invest security duration industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return table content gilead sciences inc note consolidated financial statementscontinue december subject credit risk account receivable relate product sale significant trade account receivable arise product sale united states europe certain country payment typically slow primarily greece italy portugal spain account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase financial risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding december past account receivable greece italy portugal spain total million million day past base contractual term receivable december past receivables country million million day past date experience significant loss respect collection account receivable believe past account receivable net allowance reflect consolidated balance sheet collectible perform credit evaluation customer financial condition generally require collateral certain material utilize operation obtain supplier material utilize operation facility supplier key component material name new drug application nda file food drug administration fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship viread ambisome hepsera emtriva truvada vistide supply product development clinical trial account receivable trade account receivable record net allowance cash discount prompt payment doubtful account government chargeback sale return estimate cash discount government chargeback sale return base contractual term historical trend expectation utilization rate program estimate allowance doubtful account determine base exist contractual obligation historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice historically amount uncollectible account receivable write insignificant consistent management expectation inventory inventory record low cost market cost determine firstin firstout basis periodically review composition inventory order identify obsolete slowmoving unsaleable item unsaleable item observe alternate use inventory record writedown net realizable value period impairment recognize historically inventory writedown insignificant consistent management expectation prepay royalty prepay royalty record cost base present value future royalty obligation expect pay expect level product sale incorporate related technology review prepay royalty annually indicator support writedown net recoverable value table content gilead sciences inc note consolidated financial statementscontinue december asset amortize prepay royalty cost good sell remain life underlie patent base effective royalty rate derive forecast future product sale incorporate related technology review effective royalty rate annually prospectively adjust effective rate base significant new fact circumstance arise review property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straightline method land depreciate repair maintenance cost expense incur estimate useful life year follow description estimate useful life building improvement laboratory manufacturing equipment office computer equipment leasehold improvement life relate lease office computer equipment include capitalize computer software capitalize software purchase internally develop computer software leasehold improvement capitalize lease equipment amortize short lease term asset useful life amortization capitalize lease equipment include depreciation expense capitalize interest construction progress include property plant equipment interest capitalize interest capitalize insignificant intangible asset intangible asset definite life amortize estimate useful life review impairment fact circumstance suggest carry value asset recoverable inplace lease intangible asset amortize related lease term discuss note impairment longlive asset carry value longlive asset review regular basis existence fact circumstance internally externally suggest impairment specific potential indicator impairment include significant decrease fair value asset significant change extent manner asset significant physical change asset significant adverse change legal factor business climate affect value asset adverse action assessment fda regulator accumulation cost significantly excess originally expect acquire construct asset operate cash flow loss combine history operate cash flow loss projection forecast demonstrate continue loss associate incomeproduce asset indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset eventual disposition carry asset estimate future cash flow asset liability group low level identifiable cash flow largely independent cash flow generate group undiscounte future cash flow carry asset impairment loss measure excess carrying value asset estimate fair value recognize cash flow estimate calculation base management good estimate appropriate customary assumption projection time table content gilead sciences inc note consolidated financial statementscontinue december foreign currency translation transaction contract adjustment result translate financial statement foreign subsidiary dollar exclude determination net income loss accumulate separate component stockholder equity net foreign exchange transaction gain loss report sell general administrative sga expense consolidate statement operation realize gain loss million million million hedge certain foreign currency exposure related outstanding trade account receivable forecast product sale foreign exchange forward contract general market risk contract offset correspond gain loss transaction hedge exposure credit risk contract function change interest currency exchange rate vary time gilead limit risk counterpartie contract unable perform transact major bank limit risk loss enter contract provide net settlement maturity overall risk loss event counterparty default limit unrecognize unrealized gain outstanding contract ie contract positive fair value date default enter speculative foreign currency transaction write option presently hedge net investment foreign subsidiary accounting hedge net monetary asset liability record change fair value sga expense derivative instrument designate hedge sfas nos accounting derivative instrument hedge activity collectively refer sfas selectively hedge anticipate currency exposure purchase forward contract hedge anticipate product sale year designate cash flow hedge sfas unrealized gain loss underlie forward contract record comprehensive income loss recognize earning forecast transaction occur december december net unrealize gain loss million million respectively open foreign exchange forward contract gain loss cash flow hedge record product sale increase decrease product sale million million million respectively notional amount forward exchange contract outstanding million december million december asset fair value million liability fair value million december respectively contract maturity year note discussion derivative financial instrument fair value financial instrument financial instrument consist principally cash cash equivalent marketable security accounts receivable certain noncurrent asset forward foreign exchange contract account payable longterm debt longterm obligation cash cash equivalent marketable security note forward foreign exchange contract hedge account receivable note report respective fair value balance sheet forward foreign exchange contract hedge forecast sale record fair value net relate deferred gain loss result report net balance zero gilead call convertible senior note redemption october convert share gilead common stock november believe remain financial instrument report consolidated balance sheet amount approximate current fair value table content gilead sciences inc note consolidated financial statementscontinue december income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income tax estimate base interpretation exist tax law regulation believe estimate reasonable reserve income tax relate uncertainty adequate internal external factor favorable unfavorable effect future effective income tax rate factor include limited change tax law regulation andor rate change interpretation exist tax law regulation change international organization change overall level income tax derivative financial instrument derivative recognize asset liability measure fair value enter foreign currency forward contract hedge change fair value significant monetary asset liability denominate nonfunctional currency derivative designate meet definition fair value hedge change fair value derivative hedge item recognize earning enter foreign currency forward contract generally maturitie month hedge future cash flow relate forecasted product sale foreign denominate currency derivative instrument employ eliminate minimize certain foreign currency exposure confidently identify quantify hedge relate forecasted foreign currency product sale designate document inception respective hedge designate cash flow hedge evaluate effectiveness monthly term forward contract underlie transaction match inception forward contract effectiveness calculate compare fair value contract estimate change fair value underlie hedged item effective component hedge record accumulate comprehensive income loss note substantially value report accumulate comprehensive income december reclassify earning month residual change fair value instrument include result cancellation dedesignation hedge contract ineffectiveness recognize immediately sga expense impact ineffectiveness significant consolidated statement operation gain loss million million million hedging contract recognize consolidated statement operation respectively result enter collaboration arrangement gilead hold warrant purchase stock nonpublic company complete initial public offering january note warrant exercise end quarter acquisition triangle pharmaceuticals inc january complete acquisition net asset triangle expand antiviral pipeline triangle development stage company particular focus potential therapy human immunodeficiency virus hiv include aids hepatitis b virus hbv triangle portfolio consist drug candidate clinical trial include emtricitabine treatment hiv infection emtricitabine treatment chronic hepatitis b amdoxovir treatment hiv infection clevudine treatment chronic hepatitis b july fda grant marketing approval emtriva table content gilead sciences inc note consolidated financial statementscontinue december treatment hiv october european commission grant marketing authorisation emtriva member states european union triangle acquisition account acquisition asset business combination accordance criterion outline emerge issue task force triangle development stage company commence plan principal operation lack necessary element business complete product ability access customer result operation triangle january include consolidated financial statement primarily consist rd expense less extent sga expense december arrangement contemplate propose acquisition triangle gilead million loan extend triangle work capital corporate purpose triangle issue gilead unsecured convertible promissory note completion acquisition january loan eliminate consolidated financial statement aggregate purchase price million include cash pay million outstanding stock fair value stock option assume million direct transaction cost million employee relate cost million purchase establish workforce reduction plan assume obligation change control agreement acquisition date million employee termination cost change control obligation record liability pay period approximately year december employee termination cost change control obligation fully pay follow table summarize purchase price allocation january thousand net tangible asset assemble workforce defer compensation inprocess rd million net tangible asset includes assume liability million million value assign assemble workforce amortize year estimate useful life asset defer compensation represent intrinsic value unvested stock option assume transaction december amortize remain vest period option extend january table content gilead sciences inc note consolidated financial statementscontinue december reversal defer tax asset valuation allowance fourth quarter remain million assemble workforce asset eliminate note approximately million purchase price allocate purchase inprocess rd represent fair value triangle incomplete rd program reach technological feasibility alternative future use acquisition date summary program acquisition date follows update subsequent change status development estimate acquisition date fair value program description status development millions emtricitabine hiv nucleoside analogue phase study complete prior show inhibitor hiv acquisition date marketing approval receive replication patient fda july emtriva european union approval receive european commission october emtricitabinetenofovir df fix fixeddose coformulation tenofovir acquisition date work dose combination hiv therapy emtricitabine commence potential coformulation extent work emtricitabine single agent progress march application marketing approval submit united states european union august marketing approval united states receive fda truvada fixeddose coformulation tenofovir emtricitabine marketing approval european union receive february sale commence later quarter amdoxovir hiv purine dioxolane nucleoside program phase trial acquisition offer advantage market date terminate licensing agreement nucleoside activity emory university georgia research drug resistant virus exhibit foundation inc development patient hiv infection discontinue clevudine hbv pyrimidine nucleoside analogue program phase trial acquisition show inhibitor hbv date august licensing agreement replication patient chronically infect bukwang pharm ind co ltd terminate hbv development discontinue table content gilead sciences inc note consolidated financial statementscontinue december estimate acquisition date fair value program description status development millions emtricitabine hbv inhibitor hbv replication program phase trial acquisition patient chronically infect hbv date complete december continue evaluate strategy development emtricitabine hepatitis b indication currently expect undertake significant rd activity year value purchase inprocess rd determine estimate related future net cash flow present value risk adjust discount rate discount rate significant assumption base estimate weighted average cost capital adjust upward risk associate project acquire project cash flow acquire project base estimate revenue operate profit relate project consider stage development potential product acquire time resource need complete development approval product life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound include obtain fda regulatory approval risk relate viability potential alternative treatment future target market acquisition real estate september complete purchase foster city california campus million cash purchase include building total square foot office laboratory space accordance sfas business combination sfas goodwill intangible asset purchase price allocate land building exist inplace lease base estimate relative fair value land building record million million respectively fair value building depreciate remain economic life estimate year market approach value exist lease acquire record intangible asset approximately million amortize straightline basis net rental income approximately year remain term lease accumulate amortization intangible asset million million december december respectively amortization expense million million million respectively net rental income generate lease amortization intangible asset include interest income net approximately million million lease terminate november asset impairment fourth quarter record asset impairment charge million certain longlived asset primarily leasehold improvement manufacture laboratory equipment classify hold use noncash charge drive decision terminate liposomal rd activity san dimas discontinue daunoxome daunorubicin citrate liposome injection product line impairment base analysis undiscounte cash flow generate affected asset compare carry value carrying value exceed related estimate undiscounted cash flow write carry value longlive asset estimate fair value accordance table content gilead sciences inc note consolidated financial statementscontinue december sfas accounting impairment disposal longlive asset sfas estimate fair value derive expected cash flow approach subsequent decision discontinue daunoxome product line receive unanticipated request europe ask gilead reconsider sell daunoxome result request management decide continue sell product certain country evaluate supply sale strategy respect daunoxome accordance sfas write asset continue daunoxome product line establish new cost basis asset adjust new fact circumstance gain warrant march enter agreement eyetech pharmaceuticals inc eyetech predecessor osi pharmaceuticals inc relate proprietary aptamer eye currently know macugen pursuant agreement receive warrant purchase share eyetech series b convertible prefer stock exercisable price share january eyetech complete initial public offering common stock time adjust carry value warrant estimate fair value result gain million include consolidated statement operation year end december fair value warrant estimate blackschole valuation model volatility rate discount rate end quarter exercise warrant net basis share eyetech common stock consideration exercise price subsequently hold share eyetech common stock second quarter sell eyetech share hold realize gain million include interest income net consolidated statement operation year end december availableforsale security follow summary availableforsale security record cash equivalent marketable security consolidate balance sheet estimate fair value availableforsale security base price obtain commercial pricing service thousand gross gross amortize unrealize unrealized estimate cost gain loss fair value december treasury security obligation government agency corporate debt security assetbacke security municipal debt security debt security total december treasury security obligation government agency corporate debt security assetbacke security municipal debt security debt security total table content gilead sciences inc note consolidated financial statementscontinue december december debt security consist primarily money market fund auction rate security december debt security consist primarily money market fund availableforsale security include cash equivalent million million december respectively december portfolio availableforsale security exclude million assetbacked security comprise million security contractual maturity year million security contractual maturity great year year auction rate security variable rate demand obligation aggregate fair value million contractual maturity great year contain dutch auction feature day estimate maturity assetbacked security exceed year follow table present certain information relate sale availableforsale security thousand year end december proceed sale gross realize gain sale gross realize loss sale december follow availableforsale security continuous unrealized loss position deem thantemporarily impair thousand month month great gross gross unrealize estimate unrealized estimate loss fair value loss fair value december treasury security obligation government agency corporate debt security assetbacke security municipal debt security debt security total december treasury security obligation government agency corporate debt security assetbacke security municipal debt security debt security total table content gilead sciences inc note consolidated financial statementscontinue december gross unrealized loss cause interest rate increase significant fact circumstance arise indicate deterioration creditworthiness issuer security base review security include assessment duration severity relate unrealized loss record otherthantemporary impairment security european headquarters relocation june gilead announce commercial medical administrative group european headquarters base paris france relocate london area united kingdom european headquarters regulatory safety information technology group currently locate cambridge area united kingdom believe relocation enable achieve efficiency close proximity group gilead position compete large pharmaceutical company global level gilead french subsidiary continue occupy gilead exist french facility continue maintain expand sale marketing presence france quarter relocation plan finalize gilead accrue charge million primarily consist employee severance cost termination benefit include sga expense consolidate statement operation december approximately million charge accrual include accrue compensation employee benefit consolidate balance sheet remain payment expect half additional cost relate new headquarters united kingdom include recruitment cost legal expense capital expenditure relate cost record incur base current information available believe aggregate severance relocation recruiting cost result european headquarters relocation range million million table content gilead sciences inc note consolidated financial statementscontinue december consolidated balance sheet detail thousand december inventory raw material work process finish good total property plant equipment net building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment capitalize lease equipment construction inprogress accumulate depreciation amortization include relate capitalize lease equipment respectively subtotal land total accrue compensation employee benefit accrue bonus accrue compensation employee benefit total accrue liability accrue medicaid rebate fair value forward foreign currency contract value add taxis payable accrue royalty expense liability total joint venture bristolmyer squibb december enter collaboration bristolmyer squibb company bm develop commercialize fixeddose combination gilead truvada bmss sustiva efavirenz united states structure joint venture gilead bms form limited liability company bristol myers squibb gilead sciences llc term collaboration gilead bms grant royaltyfree sublicense joint venture use respective companyowne technology return grant license joint venture use intellectual property result collaboration ownership interest joint venture gilead bms reflect respective economic interest base fraction estimate net selling price fixeddose combination product attributable table content gilead sciences inc note consolidated financial statementscontinue december truvada sustiva respectively adjust annual basis net selling price truvada change time relative net selling price sustiva gilead bmss respective economic interest joint venture vary annually gilead primary responsibility clinical development activity regulatory filing relate new product result collaboration bms gilead share marketing sale effort party provide equivalent sale force effort minimum number year daily operation joint venture govern primary joint committee gilead responsible accounting financial reporting product distribution joint venture party agree provide respective bulk active pharmaceutical ingredient joint venture estimate net selling price december joint venture hold approximately million sustiva active pharmaceutical ingredient purchase bms bmss estimate net selling price sustiva market joint venture total equity investment risk expect sufficient allow finance operational activity ongoing funding gilead bms primary beneficiary legal structure joint venture limit recourse creditor general credit asset gilead explain note consolidated financial statement include result joint venture bms reflect bmss interest joint venture minority interest collaborative arrangement contract roche september gilead enter development license agreement agreement f hoffmannla roche ltd hoffmannla roche inc roche develop commercialize therapy treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codevelope company roche agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay gilead percentage net revenue roche generate tamiflu sale turn subject reduction certain define manufacturing cost june gilead deliver notice termination roche material breach agreement november gilead resolve dispute roche relate breach agreement agree terminate relate arbitration pende party connection dispute resolution gilead roche enter amendment supplement agreement amend agreement provide formation joint manufacturing committee review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu commercial committee evaluate commercial plan strategy tamiflu united states joint supervisory committee evaluate roche overall commercial plan tamiflu global basis case consist representative gilead roche amend agreement option provide specialized sale force supplement roche marketing effort united states tamiflu royalty payable gilead net sale tamiflu sell roche remain amend agreement follow percent million worldwide net sale give calendar year b percent million worldwide net sale calendar year c percent worldwide net sale excess million calendar year amend agreement revise provision agreement relate calculation royalty payment give calendar quarter roche pay royalty base actual royalty rate applicable quarter addition royalty payable roche long subject cost good sell table content gilead sciences inc note consolidated financial statementscontinue december adjustment provide agreement roche pay gilead million gilead recognize royalty revenue consist million relate dispute royalty million relate reimbursement cost good adjustment million relate update royalty payable gilead month base current year royalty rate instead prior year effective royalty rate record total million million million tamiflu royalty respectively recognize royalty revenue roche quarter follow quarter relate tamiflu sale occur recognize contract revenue million milestone payment japanese approval tamiflu prophylaxis milestone receivable agreement emory university july gilead royalty pharma purchase royalty interest own emory university emory emtricitabine term agreement gilead royalty pharma pay respectively total purchase price million emory exchange elimination emtricitabine royalty emory worldwide net sale product contain emtricitabine result transaction capitalize prepaid royalty share million purchase price million begin amortize prepay royalty cost good sell remain life underlie patent base effective royalty rate derive forecast future product sale amortization million record royalty royalty pharma base actual emtricitabine net sale relative royalty pharma ownership underlie emory royalty interest pay royalty million royalty pharma july gilead payment million emory connection amendment restatement exist license agreement emory provide gilead great strategic flexibility development emtricitabine hepatitis b indication record payment rd expense currently expect significant relate rd year prior july pay royalty emory respect emtricitabine hiv indication worldwide license acquire acquisition triangle pay royalty million million million respectively net sale emtriva net sale truvada incorporate emtricitabine technology launch iocbrega gilead enter agreement institute organic chemistry biochemistry academy sciences czech republic rega stichte iocbrega relate certain nucleotide compound discover institution agreement gilead receive exclusive right manufacture use sell nucleotide compound gilead obligate pay iocbrega percentage net revenue receive sale product contain compound subject minimum royalty payment product cover agreement include vistide hepsera viread august agreement iocbrega amend include truvada future fixeddose combination product contain license technology gilead currently make quarterly payment iocbrega base percentage vistide hepsera viread truvada net sale pay royalty million million million iocbrega respectively december agreement iocbrega amend provide reduce royalty rate future sale tenofovir adefovir return upfront payment gilead million table content gilead sciences inc note consolidated financial statementscontinue december signing agreement payment record longterm prepay royalty classified asset balance sheet december prepay royalty recognize royalty expense expect commercial life tenofovir adefovir amortization million payment begin product launch date viread hepsera japan tobacco march enter licensing agreement japan tobacco inc japan tobacco japan tobacco grant gilead exclusive right develop commercialize novel hiv integrase inhibitor gs know jtk country world exclude japan japan tobacco retain right term agreement gilead incur upfront license fee million include rd expense quarter technology incomplete future alternative use technology additionally obligate payment japan tobacco achievement certain milestone pay royalty base future net product sale territory market drug july gilead enter licensing agreement japan tobacco japan tobacco commercialize product hiv product portfolio japan agreement include viread truvada emtriva term agreement receive upfront license fee million entitle receive additional payment achievement certain milestone japan tobacco pay royalty net sale product japan upfront fee record defer revenue amortize contract revenue period supply product japan tobacco approximately year december receive million year milestone payment japan tobacco relate japanese regulatory approval marketing authorization viread amortize remain period upfront license fee january japan tobacco submit marketing authorization application emtriva truvada japanese regulatory authority march emtriva truvada approve sale japan achillion pharmaceutical november enter exclusive license collaboration agreement achillion pharmaceuticals inc achillion agreement grant worldwide right research development commercialization certain small molecule hcv replication inhibitor involve hcv protease treatment infection hepatitis c virus hcv collaboration achillion obligate continue development compound accord mutually agree development plan completion proofofconcept clinical study hcvinfecte patient cost incur achieve proofof concept share equally gilead achillion cost incur amount million follow proofofconcept study gilead obligate assume responsibility incur cost associate development commercialization compound warrant development achillion option participate commercialization effort future product arise collaboration conjunction signing collaboration gilead pay million upfront license fee record rd expense future alternative use license technology additionally invest achillion convertible prefer stock agree payment achillion achievement certain milestone outline agreement pay royalty future net sale product arise collaboration gilead achillion begin dose patient phase study gs know ach treatment hepatitis c december net investment achillion nonmarketable convertible preferred stock million record noncurrent asset table content gilead sciences inc note consolidated financial statementscontinue december genelabs technologies september enter license research collaboration agreement genelabs technologies inc genelabs research develop commercialize certain genelab novel nucleoside inhibitor hcv polymerase treatment chronic infection cause hcv conjunction sign collaboration agreement pay million upfront license fee record rd expense future alternative use technology initially agree term year genelabs obligate lead research effort gilead option extend research term collaboration additional year gilead lead development commercialization activity agree provide annual funding time equivalent million payment genelabs record rd expense obligate additional payment achievement certain milestone pay royalty future net sale select compound develop approve relation collaboration medarex inc july enter agreement medarex inc medarex medarex buyout future royalty obligation approve product result medarexs licensing patent estate previously hold nexstar inc total agreement million schedule pay installment cash medarex stock medarexs option receive installment total million installment total million record contract revenue chiron corporation august enter nonexclusive licensing agreement chiron corporation chiron research development commercialization small molecule therapeutic select hcv drug target agreement gilead receive nonexclusive right use chiron hcv technology develop commercialize product treatment hcv term agreement pay chiron upfront license fee million record rd expense future alternative use license technology agree additional payment chiron certain clinical regulatory contractually determined milestone meet million payment chiron record rd expense additionally obligate royalty payment event product develop licensed technology glaxosmithkline april gilead gsk enter licensing agreement provide gsk right commercialize hepsera oral antiviral treatment chronic hepatitis b asia latin america certain territory agreement retain right hepsera united states canada eastern western europe australia new zealand turkey gsk receive exclusive right develop hepsera solely treatment chronic hepatitis b territory significant include china japan korea taiwan addition receive million milestone payment gsk approval hepsera million canadian approval hepsera aggregate million commercial approval hepsera japan south korea taiwan gsk responsibility development commercialization hepsera territory upfront license fee approval milestone record defer revenue total million million million recognize contract revenue respectively million balance table content gilead sciences inc note consolidated financial statementscontinue december defer revenue december expect amortize contract revenue period supply hepsera gsk agreement approximately year addition gsk require pay gilead royalty net product sale gsk generate sale hepsera epivirhbvzeffix gsk hepatitis product gsk territory gilead begin receive royalty gsk sale hepsera quarter record million million royalty revenue respectively recognize royalty revenue gsk quarter follow quarter relate hepsera sale occur eyetech pharmaceuticals inc predecessor osi march enter agreement eyetech pharmaceuticals inc eyetech predecessor osi relate macugen macugen inhibitor vascular endothelial growth factor vegf know play role development certain ophthalmic disease term agreement eyetech receive worldwide right therapeutic use macugen responsible rd cost entitle payment eyetech eyetech reach certain macugen milestone royaltie worldwide net sale macugen require payment party relate royalty february macugen approved european union entitle receive million milestone payment commercial sale december enter agreement eyetech supply macugen eyetech year record contract revenue million million million respectively connection clinical supply provide eyetech milestone achieve eyetech recognize contact revenue million milestone payment eyetech second quarter file new drug application europe united states macugen january eyetech receive fda approval sale macugen united states agreement eyetech expire later year commercial sale product develop date patent expire agreement additionally receive warrant purchase share eyetech series b convertible prefer stock exercisable price share price stock issue investor note discussion warrant eventual sale eyetech share astellas pharma inc right market ambisome subject agreement gilead astellas pharma inc astellas successor fujisawa usa inc term astella agreement amend astella sole marketing right ambisome canada exclusive marketing right ambisome rest world provide pay royalty astellas connection sale significant market asia include china india japan korea taiwan connection sale astellas purchase ambisome gilead manufacturing cost sale canada astellas purchase ambisome manufacturing cost plus specify percentage astella collect payment sale ambisome united states canada receive royalty equal astellas gross profit sale ambisome united states canada gross profit include deduction cost good sell give current effective royalty rate approximately astella net sale ambisome united states connection agreement record royalty revenue million million million table content gilead sciences inc note consolidated financial statementscontinue december longterm obligation total longterm obligation consist follow thousand december capital lease obligation monthly installment interest rate range longterm loan quarterly installment interest rate libor plus tiere contractual rate total longterm obligation current portion total longterm obligation year future minimum payment longterm obligation follow thousand capital lease longterm year end december obligation loan total represent interest total term debt agreement require comply certain financial operating covenant december compliance covenant credit facility december enter agreement syndicate bank provide fiveyear million senior credit facility million facility consist uncollateralized million term loan enter gilead biopharmaceutics ireland corporation gbic whollyowne irish subsidiary gilead uncollateralize million revolve credit facility enter parent company gilead sciences inc proceed term loan gbic december facilitate cash dividend distribution million parent company repatriation qualified foreign earning provision american job creation act ajca term million term loan minimum principal payment repay end calendar quarter begin march million interest accrue rate libor plus tiere contractual rate basis point payable arrear end quarter gbic prepay term loan time accrue interest prepay principal table content gilead sciences inc note consolidated financial statementscontinue december penalty premium outstanding interest principal december payable demand december million outstanding term loan agreement parent company whollyowne subsidiary gilead vintage park llc guarantor term million revolve credit facility interest accrue payable rate libor plus tiere contractual rate basis point payable arrear end quarter parent company prepay outstanding borrowing time accrue interest prepay principal penalty premium outstanding interest principal december payable demand capacity revolve credit facility increase maximum million million term loan repay ability irrevocably cancel unutilized portion revolve credit facility proceed obtain revolve credit facility expect work capital capital expenditure general corporate purpose include issuance letter credit million december borrowing revolve credit facility whollyowne subsidiary gilead gilead vintage park llc guarantor convertible senior note december gilead issue million convertible senior note december note convertible total share gilead common stock share convertible senior note provisionally redeemable option gilead time june specify redemption price plus accrued interest debt issuance cost million incur connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note gilead call convertible senior note redemption october issue share gilead common stock note holder conversion november redemption price equal principal note redeem plus accrue unpaid interest redemption date connection redemption gilead pay makewhole payment million note holder represent equivalent principal value note interest actually pay accrue unpaid date issuance note redemption date conversion million unamortized balance relate debt issuance cost reclassify additional paidin capital convertible subordinate note december gilead issue million convertible subordinated note december convertible subordinate note convertible total share gilead common stock share convertible subordinate note redeemable option gilead time december specify redemption price plus accrued interest debt issuance cost million incur connection issuance convertible subordinate note record noncurrent asset amortize interest expense straightline basis contractual term convertible subordinate note november gilead call convertible subordinate note redemption convert note share common stock december conversion million unamortized balance relate debt issuance cost reclassify additional paidin capital table content gilead sciences inc note consolidated financial statementscontinue december commitment contingency lease arrangement enter longterm noncancelable operating lease equipment facility facility lease foster city san dimas california durham north carolina dublin area ireland london area united kingdom expire date foster city lease fiveyear renewal option durham lease sevenyear renewal option lease ireland united kingdom year respectively rent subject increase fifth anniversary commencement date operate lease sale marketing administrative facilities europe canada australia term equipment lease include corporate aircraft vary term provide renewal option expiration lease term lease expense operating lease total approximately million million million aggregate noncancelable future minimum rental payment operating lease follow thousand year end december operating lease legal proceeding number state county municipality file complaint allege large number pharmaceutical defendant include instance gilead report inaccurate price product cause governmental entity name plaintiff overpay pharmaceutical product furnish participant medicaid program twentysix separate action file new york city numerous new york county consolidate multidistrict litigation proceeding united states district court district massachusetts august case voluntarily dismiss respect gilead knowledge gilead name additional case state alabama v abbott laboratories inc et al currently pende circuit court montgomery county alabama county erie v abbott laboratories inc et al currently pende united states district court district massachusetts state mississippi v abbott laboratories inc et al currently pende chancery court judicial district hind county mississippi complaint assert claim federal state law seek damage state alabama case treble damage attorney fee intend defend case vigorously case preliminary stage possible predict outcome amount accrue relate outcome case purport class action complaint file november united states district court northern district california gilead company chief executive officer chief financial officer executive vice president operation current senior business advisor executive vice table content gilead sciences inc note consolidated financial statementscontinue december president research development senior vice president manufacture senior vice president research complaint allege defendant violate federal security law specifically section b securities exchange act amend rule b securities exchange commission make certain allege false misleading statement plaintiff seek unspecified damage behalf purport class purchaser gilead security period july october similar action subsequently file court issue order consolidate lawsuit single action december february court issue order appoint lead plaintiff consolidated action april lead plaintiff behalf purport class file consolidated amend complaint june company individual defendant file motion dismiss consolidated amend complaint january court grant defendant motion dismiss leave amend plaintiff file second amend complaint february amend complaint march october court grant defendant notion dismiss amend complaint leave amend december plaintiff file fourth consolidated amend complaint court hear defendant motion dismiss february take matter submission render decision intend defend case vigorously outcome predict time accrue relate outcome matter party legal action arise ordinary course business believe legal action material adverse impact business result operation financial position commitment contingency normal course business subject contingency arise matter product liability claim legal proceeding shareholder suit tax matter accrue contingency accordance sfas accounting contingency normal course business enter firm purchase commitment active pharmaceutical ingredient inventoryrelate item december approximately million purchase commitment follow million million million stockholder equity prefer stock gilead share authorize preferred stock issuable series board directors board authorize determine designation power preference right series reserve share prefer stock potential issuance amend restate right agreement enter gilead prefer stock outstanding december employee stock purchase plan gilead employee stock purchase plan espp employee purchase share gilead common stock base percentage compensation purchase price share equal low market value date offer date purchase total share common stock reserve issuance espp december share total share reserve issue espp share december table content gilead sciences inc note consolidated financial statementscontinue december stock option plan gileads stockholder approve gilead adopt equity incentive plan plan replacement stock option plan plan nonemployee director stock option plan director plan plan share plus share previously authorize available issuance plan director plan reserve issuance gilead stockholder approve increase additional share common stock available issuance plan plan provide issuance type equity awards incentive stock option nonstatutory stock option stock appreciation right sar dividend equivalent right restrict stock performance unit performance share phantom share plan exercise purchase price incentive stock option nonstatutory stock option sar shall fair value gilead common stock date grant case type award exercise purchase price determine plan administrator incentive stock option typically vest year pursuant formula determine board expire year term award shall term state award agreement year date grant eligible participant include employee director consultant gilead employee eligible incentive stock option compensation committee delegate determine award grant vest term december share remain available future grant plan november gilead adopt plan issuance common stock employee consultant option issue plan discretion board incentive stock option nonqualifie stock option plan amend exercise price stock option equal fair value gilead common stock date grant option vest year pursuant formula determine board expire year plan amend restate april extend term plan stockholder approve amendment plan increase total number authorize share plan remain share available future grant plan transfer plan additionally option grant plan expire terminate exercised share common stock reserve option available future grant plan november gilead adopt director plan issuance common stock nonemployee directors pursuant predetermine formula exercise price option grant director plan equal fair value gilead common stock date grant option grant january vest year date grant quarterly percent installment initial option grant january january new director vest year date grant equal annual installment annual grant exist director vest year initial option grant january new director vest year date grant equal installment annual grant exist director vest immediately option expire year stockholder approve amendment director plan increase total number authorize share plan remain share available grant plan transfer plan additionally option grant plan expire terminate exercised share common stock reserve option available future grant plan stock plan assume gilead merger nexstar include stock option plan incentive stock plan director option plan collectively nexstar plan option pursuant table content gilead sciences inc note consolidated financial statementscontinue december nexstar plan issue outstanding july convert option purchase gilead common stock result merger remain subject original term condition share available grant future option nexstar plan stock plan assume gilead acquisition net asset triangle include stock option plan separate stock option agreement chief executive officer triangle collectively triangle plan option pursuant plan issue outstanding january convert option purchase approximately million share gilead common stock result acquisition remain subject original term condition share available grant future option triangle plan follow table summarize activity gilead nexstar triangle stock option plan option grant present table exercise price fair value underlie stock grant date share thousand year end december weight weight weight average average average exercise exercise exercise share price share price share price outstanding beginning year grant assume forfeit exercise outstanding end year exercisable end year weight average fair value option grant follow summary gilead option outstanding option exercisable december option thousand option outstanding option exercisable weighted average weight remain average weighted option contractual exercise option average exercise range exercise price outstanding life year price exercisable price total right agreement november enter right agreement right plan right plan provide distribution prefer stock purchase right dividend share gilead common stock table content gilead sciences inc note consolidated financial statementscontinue december purchase right currently exercisable certain condition involve acquisition propose acquisition person group common stock purchase right permit holder holder purchase gilead common stock discount market price time payment specify exercise price purchase right addition event certain business combination purchase right permit purchase common stock acquirer discount market price time certain condition purchase right redeemed board price purchase right purchase right voting privilege attach automatically trade gilead common stock october october board director approve amendment right plan amendment provide thing increase exercise price right plan extension term plan november october second amendment provide thing increase exercise price right plan extension term right plan october comprehensive income loss comprehensive income loss comprise net income certain change stockholder equity exclude net income exclude item comprehensive income loss include change fair value outstanding effective cash flow hedge change unrealize gain loss availableforsale security change cumulative foreign currency translation account comprehensive income loss year end december include consolidated statement stockholder equity component comprehensive income loss show net relate taxis underlie asset liability hold jurisdiction expect generate future tax benefit liability follow reclassification record connection net realize gain loss sale security cash flow hedge previously include comprehensive income loss thousands year end december net unrealize loss relate availableforsale security net tax benefit respectively net unrealized gain loss relate cash flow hedge net tax provision respectively reclassification adjustment net tax benefit provision respectively comprehensive income loss table content gilead sciences inc note consolidated financial statementscontinue december balance accumulate comprehensive income loss net taxis report consolidated balance sheet consist follow component thousand december net unrealized loss availableforsale security net unrealize gain loss cash flow hedge net foreign currency translation gain accumulate comprehensive income loss disclosure segment enterprise related information gilead operate business segment primarily focus development commercialization human therapeutic infectious disease product include segment major product viread truvada emtriva collectively hiv product ambisome account total product sale year end december respectively similar economic characteristic include nature product production process type customer distribution method regulatory environment product sale consist follow thousands year end december hiv product viread truvada emtriva total hiv product ambisome hepsera vistide daunoxome total product sale table content gilead sciences inc note consolidated financial statementscontinue december product sale productrelate contract revenue attribute country base shipto location royalty nonproduct relate contract revenue attribute country base location collaboration partner certain revenue amount reclassify geographic region conform current period presentation follow table summarize total revenue external customer collaboration partner geographic region thousand year end december united states outside united states france spain united kingdom italy germany switzerland european country country total revenue outside united states total revenue december net book value property plant equipment million approximately asset locate united states december net book value property plant equipment million approximately asset locate united states follow table summarize revenue customer individually account total revenue total revenue year end december cardinal health inc amerisourcebergen corp mckesson corp table content gilead sciences inc note consolidated financial statementscontinue december income taxis provision benefit income taxis consist follow thousands year end december federal current deferred state current defer foreign current defer foreign pretax income loss million million million company foreign subsidiary generate operating loss reflect cost build commercial infrastructure europe foreign subsidiary investment rd effort cumulative unremitted foreign earning consider permanently invest outside united states taxis provide approximately million december residual tax liability amount remit approximately million difference provision benefit income taxis compute apply federal statutory income tax rate income loss provision benefit income taxis explain thousands year end december income loss provision benefit income taxis tax federal statutory rate state taxis net federal benefit foreign earning different rate benefit qualified foreign earning repatriation benefit loss change valuation allowance inprocess rd charge foreign loss different rate provision benefit income taxis tax benefit associate stock option exercise employee stock purchase plan million year end december benefit credit additional paidin capital table content gilead sciences inc note consolidated financial statementscontinue december defer income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component company defer tax asset liability follow thousand december defer tax asset net operating loss carryforward reserve accrual currently deductible depreciation relate research credit carryforward capitalize intangible capitalize rd expense net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability unrealize gain investment unremitte foreign earning total defer tax liability net defer tax asset company valuation allowance december valuation allowance million december valuation allowance decrease million million million year end december respectively conclude base standard set forth sfas accounting income taxis likely realize benefit relate deferred tax asset approximately million valuation allowance december relate tax benefit stock option deduction credit additional paidin capital december company federal net operating loss carryforward approximately million federal net operating loss carryforward expire date utilize addition company federal tax credit carryforward approximately million expire utilize utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code similar state provision annual limitation result expiration net operating loss credit utilization october ajca sign law ajca allow deduction certain qualified foreign earning repatriate define ajca company elect apply provision qualify earning repatriation fiscal earning repatriation result time tax benefit approximately million include reversal defer tax liability previously accrue unremitted foreign earning million december table content gilead sciences inc note consolidated financial statementscontinue december defer compensation plan gilead maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code gilead plan gilead plan employee contribute eligible annual compensation gilead make matching contribution gilead plan contribute employee contribution annual maximum match total matching contribution expense gilead plan million million gilead maintain defer compensation plan director officer defer compensation income tax purpose defer compensation plan nonqualifie defer compensation plan subject qualification requirement section internal revenue code compensation defer december subject requirement section internal revenue code plan officer contribute annual salary annual bonus director contribute annual retainer fee amount defer participant deposit rabbi trust record noncurrent asset consolidate balance sheet begin director elect receive portion annual cash retainer phantom share give participant right receive equal value specify number share specify period time payable cash share establish plan administrator december issue phantom share participant elect distribution date available plan receive defer compensation payment table content gilead sciences inc note consolidated financial statementscontinue december quarterly result operation unaudite follow amount thousand share amount st quarter nd quarter rd quarter th quarter total revenue gross profit product sale total cost expense net income net income sharebasic net income sharedilute total revenue gross profit product sale total cost expense net income net income sharebasic net income sharedilute fourth quarter gilead recognize million royalty revenue relate resolution dispute roche fourth quarter gilead record onetime tax benefit million relate repatriation qualified foreign earning ajca quarter gilead record pretax gain million relate warrant purchase capital stock eyetech complete initial public offering fourth quarter gilead record expense million connection makewhole payment convertible senior note holder relation redemption conversion convertible senior note september gilead implement twoforone stock split form stock dividend share amount period present restate reflect stock split table content gilead sciences inc schedule ii valuation qualifying account balance balance begin charge end period expense deduction period year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset allowance doubtful account sale return cash discount chargeback table content